

(19) **DANMARK**



Patent- og  
Varemærkestyrelsen

(12)

## Oversættelse af europæisk patentskrift

(10) **DK/EP 3142643 T3**

- 
- (51) Int.Cl.: **A 61 K 31/7036 (2006.01)** **A 61 K 9/00 (2006.01)** **A 61 K 9/127 (2006.01)**  
**A 61 P 31/04 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2019-10-14**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2019-07-10**
- (86) Europæisk ansøgning nr.: **15791964.8**
- (86) Europæisk indleveringsdag: **2015-05-15**
- (87) Den europæiske ansøgnings publiceringsdag: **2017-03-22**
- (86) International ansøgning nr.: **US2015031079**
- (87) Internationalt publikationsnr.: **WO2015175939**
- (30) Prioritet: **2014-05-15 US 201461993439 P** **2014-08-26 US 201462042126 P**  
**2014-09-09 US 201462048068 P** **2014-09-26 US 201462056296 P**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **Insmmed Incorporated, 10 Finderne Ave, Building 10, Bridgewater, NJ 08807-3365, USA**
- (72) Opfinder: **EAGLE, Gina, 11 Glen Alpin Road, Morristown, New Jersey 07960, USA**  
**GUPTA, Renu, 412 Salem Crossing Road, Moorestown, New Jersey 08057, USA**
- (74) Fuldmægtig i Danmark: **MURGITROYD & COMPANY, Scotland House, 165-169 Scotland Street, Glasgow G5 8PL, Storbritannien**
- (54) Benævnelse: **FREMGANGSMÅDER TIL BEHANDLING AF IKKE-TUBERKULØSE MYKOBAKTERIELLE LUNGEINFEKTIONER**
- (56) Fremdragne publikationer:  
**US-A- 4 952 405**  
**US-A- 5 756 121**  
**US-A1- 2004 142 026**  
**US-A1- 2007 077 290**  
**US-A1- 2009 104 256**  
**US-A1- 2012 192 861**  
**US-A1- 2013 136 788**  
**US-A1- 2013 330 400**  
**N Düzgünes ET AL: "Treatment of intracellular Mycobacterium avium complex infection by free and liposome-encapsulated sparflaxacin", Antimicrobial Agents and Chemotherapy, 1 November 1996 (1996-11-01), pages 2618-2621, XP055429313, UNITED STATES Retrieved from the Internet:**  
**URL: <http://aac.asm.org/content/40/11/2618.full.pdf>**  
**SASHA J. ROSE ET AL: "Delivery of Aerosolized Liposomal Amikacin as a Novel Approach for the Treatment of Nontuberculous Mycobacteria in an Experimental Model of Pulmonary Infection", PLOS ONE, vol. 9, no. 9, 29**

Fortsættes ...



# DESCRIPTION

## BACKGROUND

**[0001]** Certain technologies suitable for administration by inhalation employ liposomes and lipid complexes supply a prolonged therapeutic effect of drug in the lung. These technologies also provide the drug with sustained activities, and the ability to target and enhance the uptake of the drug into sites of disease.

**[0002]** Inhalation delivery of liposomes is complicated by their sensitivity to shear-induced stress during nebulization, which can lead to change in physical characteristics (e.g., entrapment, size). However, as long as the changes in characteristics are reproducible and meet acceptability criteria, they need not be prohibitive to pharmaceutical development.

**[0003]** Pulmonary infection with non-tuberculous mycobacterium (NTM) in the susceptible host can lead to potentially severe morbidity and even mortality among those affected. As infection rates are rising, pulmonary nontuberculous mycobacterial disease (PNTM) represents an emerging public health concern in the United States. NTM are ubiquitous in the environment. Over 80% of pulmonary NTM (PNTM) infections in the US are due to *Mycobacterium avium* complex (MAC). In addition, *M. Kansasii*, *M. abscessus*, and *M. fortuitum* are regularly isolated.

**[0004]** The prevalence of pulmonary NTM infections in the United States has more than doubled in the last 15 years. The ATS/IDSA PNTM reported 2-year period prevalence of pulmonary NTM infections is 8.6/100,000 persons. The prevalence of pulmonary NTM infections increases with age with 20.4/100,000 in those at least 50 years of age and is especially prevalent in females (median age: 66 years; female: 59%).

**[0005]** In the susceptible individual, pulmonary NTM infections can be serious or life threatening. Available therapies may be poorly tolerated, and may have significant adverse events. The present invention addresses this and other needs by providing methods for treating pulmonary NTM infections in patients in need thereof.

**[0006]** N Duzgunes ET AL: "Treatment of intracellular *Mycobacterium avium* complex infection by free and liposome-encapsulated sparfloxacin", *Antimicrobial Agents and Chemotherapy*, 1 November 1996 (1996-11-01), pages 2618-2621, XP055429313, investigates whether the fluoroquinolone sparfloxacin is effective in treating MAC infection in the murine macrophage-like cell line J774.

**[0007]** SASHA J. ROSE ET AL: "Delivery of Aerosolized Liposomal Amikacin as a Novel Approach for the Treatment of Nontuberculous Mycobacteria in an Experimental Model of Pulmonary Infection", *PLOS ONE*, vol. 9, no. 9, 29 September 2014 (2014-09-29), page e108703, XP055205825, DOI: 10.1371/journal.pone.0108703 investigates the activity of

liposomal amikacin for inhalation (LAI) against NTM in vitro as well as in a murine model of respiratory infection.

**[0008]** US5756121A discloses a liposomal aminoglycoside formulation comprising a neutral lipid, a negatively charged lipids and a sterol.

**[0009]** US 2007/077290A1 discloses a method of preparing lipid based drug formulations with low lipid/drug ratios using coacervation techniques.

**[0010]** US 2009/104256A1 and US 2013/136788A1 disclose methods of treating pulmonary disorders comprising administering to the patient an effective dose of a nebulized liposomal amikacin formulation for at least one treatment cycle.

**[0011]** US 2004/142026A1 discloses a method of treating or ameliorating pulmonary infection in a cystic fibrosis patient comprising pulmonary administration of an effective amount of a liposomal/complexed antiinfective to the patient.

**[0012]** US 4952405A discloses a method of selectively enhancing efficacy of gentamicin, when used in the treatment of Mycobacterium avium Complex (MAC), by intravenous administration of the drug in liposomal form.

**[0013]** US 2013/330400A1 discloses a system for treating a subject with a pulmonary infection, for example, a nontuberculous mycobacterial pulmonary infection, a Burkholderia pulmonary infection, a pulmonary infection associated with bronchiectasis, or a Pseudomonas pulmonary infection.

**[0014]** US 2012/192861A1 discloses formulations of pirfenidone or pyridone analog compounds for aerosolization and use of such formulations for aerosol administration of pirfenidone or pyridone analog compounds for the prevention or treatment of various fibrotic and inflammatory diseases.

## **SUMMARY**

**[0015]** The present invention provides a pharmaceutical composition comprising from 450 mg to 650 mg amikacin, or a pharmaceutically acceptable salt thereof, encapsulated in a plurality of liposomes, wherein the lipid component of the plurality of liposomes consists of a dipalmitoylphosphatidylcholine (DPPC) and cholesterol, for use in, treating or providing prophylaxis against a *Mycobacterium avium* complex (MAC) lung infection in a patient in need of treatment or prophylaxis, wherein the composition is administered, once daily in a single dosing session, for an administration period of at least three months to the lungs of the patient by aerosolizing the pharmaceutical composition via a nebulizer to provide an aerosolized pharmaceutical composition comprising a mixture of free amikacin, or pharmaceutically acceptable salt thereof and liposomal complexed amikacin, or pharmaceutically acceptable salt

thereof, wherein during the administration period or subsequent to the administration period, the patient experiences a MAC culture conversion to negative. Further embodiments of the invention are specified in the dependent claims. Aspects and embodiments disclosed herein which do not fall within the scope of the claims do not form part of the invention.

**[0016]** The disclosure provides methods for treating or providing prophylaxis against a nontuberculous mycobacterial (NTM) infection (pulmonary infection caused or due to one or more nontuberculous mycobacteria), via inhalation administration of an effective amount of a composition comprising a liposomal complexed aminoglycoside, or a pharmaceutically acceptable salt thereof, to a patient in need thereof. The patient in need of treatment, in one embodiment, is a cystic fibrosis patient, a bronchiectasis patient, suffers from asthma or suffers from chronic obstructive pulmonary disorder (COPD).

**[0017]** In one embodiment of the disclosure, the NTM infection is a pulmonary NTM infection selected from an *M. avium*, *M. avium* subsp. *hominissuis* (MAH), *M. abscessus*, *M. chelonae*, *M. bolletii*, *M. kansasii*, *M. ulcerans*, *M. avium*, *M. avium* complex (MAC) (*M. avium* and *M. intracellulare*), *M. conspicuum*, *M. kansasii*, *M. peregrinum*, *M. immunogenum*, *M. xenopi*, *M. marinum*, *M. malmoense*, *M. marinum*, *M. mucogenicum*, *M. nonchromogenicum*, *M. scrofulaceum*, *M. simiae*, *M. smegmatis*, *M. szulgai*, *M. terrae*, *M. terrae* complex, *M. haemophilum*, *M. genavense*, *M. gordonae*, *M. ulcerans*, *M. fortuitum*, *M. fortuitum* complex (*M. fortuitum* and *M. chelonae*) infection or a combination thereof. In a further embodiment, the NTM infection is an *M. avium* complex (MAC) (*M. avium* and *M. intracellulare*) infection. In one embodiment, the NTM infection is a pulmonary recalcitrant NTM infection.

**[0018]** In one embodiment, the composition comprising the liposomal complexed aminoglycoside is a dispersion (e.g., a liposomal solution or suspension). The liposomal portion of the composition comprises a lipid component that includes electrically neutral lipids. In further embodiments, the electrically neutral lipids comprise a phosphatidylcholine and a sterol (e.g., dipalmitoylphosphatidylcholine and cholesterol). In the embodiments of the invention, the aminoglycoside is amikacin or a pharmaceutically acceptable salt thereof. In even a further embodiment, the aminoglycoside is amikacin sulfate.

**[0019]** In one embodiment, the method for treating or providing prophylaxis against an NTM infection comprises administering an aerosolized pharmaceutical composition to the lungs of the patient in need thereof; wherein the aerosolized pharmaceutical composition comprises a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and the lipid component of the liposome consists of electrically neutral lipids. In further embodiments, the electrically neutral lipids comprise a phosphatidylcholine and a sterol (e.g., dipalmitoylphosphatidylcholine and cholesterol). In the embodiments of the invention, the aminoglycoside is amikacin or a pharmaceutically acceptable salt thereof. In even a further embodiment, the aminoglycoside is amikacin sulfate.

**[0020]** The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and/or NTM culture conversion to negative

during or after the administration period. For example, one embodiment, the method provided herein results in the patient having an NTM culture conversion to negative after an administration period.

**[0021]** In one embodiment of the disclosure, the aminoglycoside or pharmaceutically acceptable salt thereof is amikacin, apramycin, arbekacin, astromicin, capreomycin, dibekacin, framycetin, gentamicin, hygromycin B, isepamicin, kanamycin, neomycin, netilmicin, paromomycin, rhodestreptomycin, ribostamycin, sisomicin, spectinomycin, streptomycin, tobramycin, verdamycin, a pharmaceutically acceptable salt thereof, or a combination thereof. In embodiments of the invention, the aminoglycoside is amikacin. In another embodiment of the disclosure, the aminoglycoside is selected from an aminoglycoside set forth in Table 1, below, a pharmaceutically acceptable salt thereof, or a combination thereof.

<b>Table 1. Aminoglycosides for use with the present disclosure</b>			
AC4437	dibekacin	K-4619	sisomicin
amikacin	dactimicin	isepamicin	rhode streptomycin
apramycin	etimicin	KA-5685	sorbistin
arbekacin	framycetin	kanamycin	spectinomycin
astromicin	gentamicin	neomycin	sporaricin
bekanamycin	H107	netilmicin	streptomycin
boholmycin	hygromycin	paromomycin	tobramycin
brulamycin	hygromycin B	plazomicin	verdamycin
capreomycin	inosamycin	ribostamycin	vertilmicin

**[0022]** The pharmaceutical compositions provided herein in one embodiment are dispersions of liposomes (i.e., liposomal dispersions or aqueous liposomal dispersions which can be either liposomal solutions or liposomal suspensions). In one embodiment of the disclosure, the lipid component of the liposomes consists essentially of one or more electrically neutral lipids. In a further embodiment of the disclosure, the electrically neutral lipid comprises a phospholipid and a sterol. In a further embodiment of the disclosure, the phospholipid is dipalmitoylphosphatidylcholine (DPPC) and the sterol is cholesterol.

**[0023]** In one embodiment, the lipid to aminoglycoside weight ratio in the aminoglycoside pharmaceutical composition (aminoglycoside liposomal solution or suspension) is about 2:1, about 2:1 or less, about 1:1, about 1:1 or less, about 0.75:1 or less, or about 0.7:1. In another embodiment, the lipid to aminoglycoside weight ratio in the composition is from about 0.10:1 to about 1.25:1, from about 0.10:1 to about 1.0:1, from about 0.25:1 to about 1.25:1, from about 0.5:1 to about 1:1.

**[0024]** The methods provided herein comprise administration of the liposomal aminoglycoside composition via nebulization or aerosolization. The method in these embodiments therefore entails generation of an aerosolized aminoglycoside composition. In one embodiment, upon

nebulization, the aerosolized composition has an aerosol droplet size of about 1  $\mu\text{m}$  to about 3.8  $\mu\text{m}$ , about 1.0  $\mu\text{m}$  to 4.8  $\mu\text{m}$ , about 3.8  $\mu\text{m}$  to about 4.8  $\mu\text{m}$ , or about 4.0  $\mu\text{m}$  to about 4.5  $\mu\text{m}$ . In embodiments of the invention, the aminoglycoside is amikacin. In even a further embodiment, the amikacin is amikacin sulfate.

**[0025]** In one embodiment, about 70% to about 100% of the aminoglycoside present in the composition is liposomal complexed, e.g., encapsulated in a plurality of liposomes, prior to administration to the patient in need of treatment. In an embodiment of the disclosure, the aminoglycoside is selected from an aminoglycoside provided in Table 1. In embodiments of the invention, the aminoglycoside is an amikacin (e.g., as amikacin sulfate). In even a further embodiment, about 80% to about 100% of the amikacin is liposomal complexed, or about 80% to about 100% of the amikacin is encapsulated in a plurality of liposomes, prior to administration to the patient in need of treatment. In another embodiment, prior to administration to the patient in need of treatment (i.e., prior to nebulization), about 80% to about 100%, about 80% to about 99%, about 90% to about 100%, 90% to about 99%, or about 95% to about 99% of the aminoglycoside present in the composition is liposomal complexed.

**[0026]** In one embodiment, the percent liposomal complexed (also referred to herein as "liposomal associated") aminoglycoside post-nebulization is from about 50% to about 80%, from about 50% to about 75%, from about 50% to about 70%, from about 55% to about 75%, or from about 60% to about 70%. In a further embodiment of the disclosure, the aminoglycoside is selected from an aminoglycoside provided in Table 1. In embodiments of the invention, the aminoglycoside is amikacin. In an embodiment, the amikacin is amikacin sulfate. In one embodiment, the aerosolized composition (i.e., post nebulization) comprises from about 65% to about 75% liposomal complexed aminoglycoside and from about 25% to about 35% free aminoglycoside. In a embodiments of the invention, the aminoglycoside is amikacin. In an embodiment, the amikacin is amikacin sulfate.

**[0027]** In one embodiment of the disclosure, the pulmonary infection treated by the methods provided herein is a *Mycobacterium abscessus* pulmonary infection or a *Mycobacterium avium complex* pulmonary infection. In one or more of the preceding embodiments, the patient is a cystic fibrosis patient, a bronchiectasis patient, an asthma patient or a COPD patient.

**[0028]** In one embodiment, a patient with cystic fibrosis is treated for a pulmonary infection with one of the compositions or systems provided herein. In a further embodiment of the disclosure, the pulmonary infection is caused by *Mycobacterium abscessus* or *Mycobacterium avium complex*.

**[0029]** In one embodiment, the concentration of the aminoglycoside in the liposomal aminoglycoside composition is about 50 mg/mL or greater. In a further embodiment, the concentration of the aminoglycoside in the liposomal complexed aminoglycoside is about 60 mg/mL or greater. In a further embodiment, the concentration of the aminoglycoside in the liposomal complexed aminoglycoside is about 70 mg/mL or greater, for example about 70 mg/mL to about 75 mg/mL. In a further embodiment, the aminoglycoside is selected from an

aminoglycoside provided in Table 1. In embodiments of the invention, the aminoglycoside is amikacin (e.g., amikacin sulfate).

### **BRIEF DESCRIPTION OF THE FIGURES**

[0030]

**Figure 1** shows the study design for a randomized, double-blind, placebo controlled study of liposomal complexed amikacin in patients with recalcitrant nontuberculous mycobacterial (NTM) lung infection, described in Example 1.

**Figure 2** shows the patient distribution for the randomized, double-blind, placebo controlled study of liposomal complexed amikacin in patients with recalcitrant nontuberculous mycobacterial lung infection, described in Example 1.

**Figure 3** shows the number of patients in each NTM treatment group.

**Figure 4** shows the log scale (LS) mean change from baseline on the full semi quantitative scale for mycobacterial culture for the modified intent to treat patient (mITT) population as a function of study day for both the double-blind phase and the open-label phase of the study set forth in Example 1.

**Figure 5 (top)** is a bar graph showing the proportion of patients with NTM culture conversion to negative at various time points during the randomized, double-blind, placebo controlled study (modified intent to treat population). **Figure 5 (bottom)** is a bar graph showing the proportion of MAC patients with NTM culture conversion to negative at various time points.

**Figure 6** shows patients with at least 1 NTM culture negative result at various time points during the randomized, double-blind, placebo controlled study.

**Figure 7 (top)** is a graph showing the change from baseline in the six-minute walk test at day 84 and day 168 (mITT population) and **Figure 7 (bottom)** is a graph of the mean change from baseline in distance walked (meters) in the 6MWT in patients receiving LAI vs. placebo at day 84 (last observation carried forward, modified intent to treat population).

**Figure 8 (top)** is a graph showing the average meters walked in the six-minute walk test at day 84 and day 168 (all patients). **Figure 8 (bottom)** is a graph showing the mean change from baseline to Days 84 and 168 in distance walked (meters) in the 6MWT in patients with culture conversion to negative ( $\geq 3$  negative cultures) vs. those without culture conversion to negative (last observation carried forward- modified intent to treat population).

**Figure 9** shows the study design for a randomized, placebo controlled study of liposomal encapsulated amikacin (ARIKAYCE or LAI) in patients with Non-Cystic Fibrosis (Non-CF) *M. avium* complex (MAC) lung infection, described in Example 2.



**DETAILED DESCRIPTION**

**[0031]** Disclosed herein are methods for treating a pulmonary infection in a patient in need thereof, e.g., administering an aminoglycoside pharmaceutical composition to the lungs of the patient, for example, via nebulization.

**[0032]** The term "about," as used herein, refers to plus or minus ten percent of the object that "about" modifies.

**[0033]** The term "treating" includes: (1) preventing or delaying the appearance of clinical symptoms of the state, disorder or condition developing in the subject that may be afflicted with or predisposed to the state, disorder or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder or condition; (2) inhibiting the state, disorder or condition (i.e., arresting, reducing or delaying the development of the disease, or a relapse thereof in case of maintenance treatment, of at least one clinical or subclinical symptom thereof); and/or (3) relieving the condition (i.e., causing regression of the state, disorder or condition or at least one of its clinical or subclinical symptoms). The benefit to a subject to be treated is either statistically significant or at least perceptible to the subject or to the physician.

**[0034]** "Prophylaxis," as used herein, can mean complete prevention of an infection or disease, or prevention of the development of symptoms of that infection or disease; a delay in the onset of an infection or disease or its symptoms; or a decrease in the severity of a subsequently developed infection or disease or its symptoms.

**[0035]** The term "antibacterial" is art-recognized and refers to the ability of compounds to prevent, inhibit or destroy the growth of microbes of bacteria. Examples of bacteria are provided above.

**[0036]** The term "antimicrobial" is art-recognized and refers to the ability of the aminoglycoside compounds to prevent, inhibit, delay or destroy the growth of microbes such as bacteria, fungi, protozoa and viruses.

**[0037]** "Effective amount" means an amount of an aminoglycoside (e.g., amikacin) sufficient to result in the desired therapeutic response. The effective amount of the composition provided herein comprises both free and liposomal complexed aminoglycoside. For example, the liposomal complexed aminoglycoside, in embodiments of the invention, comprises aminoglycoside encapsulated in a liposome, or complexed with a liposome, or a combination thereof.

**[0038]** "Liposomal dispersion" refers to a solution or suspension comprising a plurality of liposomes.

**[0039]** An "aerosol," as used herein, is a gaseous suspension of liquid particles. The aerosol provided herein comprises particles of the liposomal dispersion.

**[0040]** A "nebulizer" or an "aerosol generator" is a device that converts a liquid into an aerosol of a size that can be inhaled into the respiratory tract. Pneumonic, ultrasonic, electronic nebulizers, e.g., passive electronic mesh nebulizers, active electronic mesh nebulizers and vibrating mesh nebulizers are amenable for use with the invention if the particular nebulizer emits an aerosol with the required properties, and at the required output rate.

**[0041]** The process of pneumatically converting a bulk liquid into small droplets is called atomization. The operation of a pneumatic nebulizer requires a pressurized gas supply as the driving force for liquid atomization. Ultrasonic nebulizers use electricity introduced by a piezoelectric element in the liquid reservoir to convert a liquid into respirable droplets. Various types of nebulizers are described in Respiratory Care, Vol. 45, No. 6, pp. 609-622 (2000). The terms "nebulizer" and "aerosol generator" are used interchangeably throughout the specification. "Inhalation device," "inhalation system" and "atomizer" are also used in the literature interchangeably with the terms "nebulizer" and "aerosol generator."

**[0042]** "Mass median diameter" or "MMD" is determined by laser diffraction or impactor measurements, and is the average particle diameter by mass.

**[0043]** "Mass median aerodynamic diameter" or "MMAD" is normalized regarding the aerodynamic separation of aqua aerosol droplets and is determined impactor measurements, e.g., the Anderson Cascade Impactor (ACI) or the Next Generation Impactor (NGI). The gas flow rate, in one embodiment, is 28 Liter per minute by the Anderson Cascade Impactor (ACI) and 15 Liter per minute by the Next Generation Impactor (NGI). "Geometric standard deviation" or "GSD" is a measure of the spread of an aerodynamic particle size distribution.

**[0044]** Nontuberculous mycobacteria are organisms found in the soil and water that can cause serious lung disease in susceptible individuals, for which there are currently limited effective treatments and no approved therapies. The prevalence of NTM disease is reported to be increasing, and according to reports from the American Thoracic Society is believed to be greater than that of tuberculosis in the U.S. According to the National Center for Biotechnology Information, epidemiological studies show that presence of NTM infection is increasing in developing countries, perhaps because of the implementation of tap water. Women with characteristic phenotype are believed to be at higher risk of acquiring NTM infection along with patients with defects on cystic fibrosis transmembrane conductance regulators. Generally, high risk groups with NTM lung disease for increased morbidity and mortality are those with cavitory lesions, low BMI, advanced age, and a high comorbidity index.

**[0045]** NTM lung disease is often a chronic condition that can lead to progressive inflammation and lung damage, and is characterized by bronchiectasis and cavitory disease. NTM infections often require lengthy hospital stays for medical management. Treatment usually involves multi-drug regimens that can be poorly tolerated and have limited effectiveness, especially in

patients with severe disease or in those who have failed prior treatment attempts. According to a company-sponsored patient chart study conducted by Clarity Pharma Research, approximately 50,000 patients suffering from NTM lung disease visited physician offices in the U.S. during 2011.

**[0046]** Management of pulmonary disease caused by nontuberculous mycobacteria (NTM) infection includes lengthy multidrug regimens, which are often associated with drug toxicity and suboptimal outcomes. Achieving NTM culture negativity is one of the objectives of treatment and represents the most clinically important microbiologic endpoint in patients with NTM lung infection.

**[0047]** Disclosed herein are methods for treating a pulmonary nontuberculous mycobacterial (NTM) infection in a patient in need thereof. The method in one embodiment comprises administration to the patient a composition comprising a liposomal complexed aminoglycoside, or a pharmaceutically acceptable salt thereof for an administration period. The liposomal complexed aminoglycoside, in one embodiment, comprises the aminoglycoside or pharmaceutically acceptable salt thereof encapsulated in a plurality of liposomes. The plurality of liposomes in one embodiment, include a lipid component that consists of neutral lipids. In one embodiment of the invention, the neutral lipids comprise a phospholipid and a sterol. In one embodiment, the phospholipid is a phosphatidylcholine. In one embodiment, the phosphatidylcholine is dipalmitoylphosphatidylcholine (DPPC). In one embodiment, the sterol is cholesterol. In one embodiment, the nontuberculous mycobacterial lung infection is a recalcitrant nontuberculous mycobacterial lung infection. The patient, in one embodiment, exhibits an increased number of meters walked in the 6MWT, as compared to prior to treatment and an NTM culture conversion to negative, during the administration period or after the administration period.

**[0048]** The therapeutic response can be any response that a user (e.g., a clinician) will recognize as an effective response to the therapy. The therapeutic response will generally be a reduction, inhibition, delay or prevention in growth of or reproduction of one or more NTM, or the killing of one or more NTM. A therapeutic response may also be reflected in an improvement in pulmonary function, for example forced expiratory volume in one second (FEV<sub>1</sub>). In one embodiment, where a patient is treated for an NTM lung infection, the therapeutic response is measured as the change from baseline on the full semi quantitative scale for mycobacterial culture or an improvement in the distance walked in the 6 minute walk test (6MWT). It is further within the skill of one of ordinary skill in the art to determine appropriate treatment duration, appropriate doses, and any potential combination treatments, based upon an evaluation of therapeutic response.

**[0049]** The NTM lung infection treatable by the methods and compositions described herein, in one embodiment of the disclosure, is *M. avium*, *M. avium* subsp. *hominissuis* (MAH), *M. abscessus*, *M. chelonae*, *M. bolletii*, *M. kansasii*, *M. ulcerans*, *M. avium*, *M. avium* complex (MAC) (*M. avium* and *M. intracellulare*), *M. conspicuum*, *M. kansasii*, *M. peregrinum*, *M. immunogenum*, *M. xenopi*, *M. marinum*, *M. malmoense*, *M. marinum*, *M. mucogenicum*, *M.*

*nonchromogenicum*, *M. scrofulaceum*, *M. simiae*, *M. smegmatis*, *M. szulgai*, *M. terrae*, *M. terrae* complex, *M. haemophilum*, *M. genavense*, *M. asiaticum*, *M. shimoidei*, *M. gordonae*, *M. nonchromogenicum*, *M. triplex*, *M. lentiflavum*, *M. celatum*, *M. fortuitum*, *M. fortuitum* complex (*M. fortuitum* and *M. chelonae*) or a combination thereof. In further embodiments, the nontuberculous mycobacterial lung infection is *M. avium* complex (MAC) (*M. avium* and *M. intracellulare*), *M. abscessus* or *M. avium*. In a further embodiment, the *M. avium* infection is *M. avium* subsp. *hominissuis*. In embodiments of the invention, the nontuberculous mycobacterial lung infection is *M. avium* complex (MAC) (*M. avium* and *M. intracellulare*). In an embodiment, the NTM lung infection is a recalcitrant nontuberculous mycobacterial lung infection.

**[0050]** As described throughout, the compositions and systems described herein are used to treat an infection caused by a nontuberculous mycobacterium (NTM). In one embodiment of the disclosure, the compositions and systems described herein are used to treat an infection caused by *Mycobacterium abscessus*, *Mycobacterium avium* or *M. avium* complex. In even a further embodiment, the *Mycobacterium avium* infection is *Mycobacterium avium* subsp. *hominissuis*.

**[0051]** In one embodiment of the disclosure, a patient is treated for a *Mycobacterium abscessus*, *M. kansasii*, *M. abscessus*, *M. fortuitum*, *Mycobacterium avium* or a *M. avium* complex (MAC) lung infection via inhalation delivery of a liposomal aminoglycoside composition. In a further embodiment, the aminoglycoside is amikacin sulfate and is administered once per day for in a single dosing session. In embodiments of the invention, the NTM lung infection is MAC.

**[0052]** The NTM lung infection, in one embodiment, is associated with cavitary lesions. In one embodiment, the NTM lung infection is a nodular infection. In a further embodiment, the NTM lung infection is a nodular infection with minimal cavitary lesions.

**[0053]** In one embodiment of the disclosure, the aminoglycoside or pharmaceutically acceptable salt thereof, administered via the methods described herein, is selected from amikacin, apramycin, arbekacin, astromycin, capreomycin, dibekacin, framycetin, gentamicin, hygromycin B, isepamicin, kanamycin, neomycin, netilmicin, paromomycin, rhodestreptomycin, ribostamycin, sisomicin, spectinomycin, streptomycin, tobramycin, verdamicin, or a pharmaceutically acceptable salt thereof. In embodiments of the invention, the aminoglycoside is amikacin. In even a further embodiment, the amikacin is amikacin sulfate. In another embodiment of the disclosure, the aminoglycoside is selected from an aminoglycoside set forth in Table 2, below, a pharmaceutically acceptable salt thereof, or a combination thereof. For example, a pharmaceutically acceptable salt such as a sulfate salt of one or more of the aminoglycosides set forth in Table 2 can be formulated in a liposomal composition and administered to a patient in need of NTM treatment, e.g., via pulmonary delivery by a nebulizer.

---

**Table 2. Aminoglycosides for use with the present disclosure**

AC4437	dibekacin	K-4619	sisomicin
amikacin	dactimicin	isepamicin	rhodestreptomycin
arbekacin	etimicin	KA-5685	sorbistin
apramycin	framycetin	kanamycin	spectinomycin
astromicin	gentamicin	neomycin	sporaricin
bekanamycin	H107	netilmicin	streptomycin
boholmycin	hygromycin	paromomycin	tobramycin
brulamycin	hygromycin B	plazomicin	verdamicin
capreomycin	inosamycin	ribostamycin	vertilmicin

**[0054]** In one embodiment, a pharmaceutical composition comprises a combination of aminoglycosides, or pharmaceutically acceptable salts thereof, e.g., a combination of two or more aminoglycosides, or pharmaceutically acceptable salts thereof, as set forth in Table 2. In one embodiment, the composition comprising the liposomal complexed aminoglycoside comprises from 1 to about 5 aminoglycosides, or pharmaceutically acceptable salts thereof. In another embodiment, the composition comprising the liposomal complexed aminoglycoside comprises at least 1, at least 2, at least 3, at least 4, at least 5, or at least 6, of the aminoglycosides set forth in table 2 (or pharmaceutically acceptable salts of the aminoglycosides. In another embodiment of the disclosure, a pharmaceutical composition comprises between 1 and 4 aminoglycosides, or pharmaceutically acceptable salts thereof. In embodiments of the invention, the combination comprises amikacin, e.g., as amikacin sulfate.

**[0055]** In one embodiment, the aminoglycoside is an aminoglycoside free base, or its salt, solvate, or other non-covalent derivative. In embodiments of the invention, the aminoglycoside is amikacin. Included as suitable aminoglycosides used in the drug compositions are pharmaceutically acceptable addition salts and complexes of drugs. In cases where the compounds may have one or more chiral centers, unless specified, the present invention comprises each unique racemic compound, as well as each unique nonracemic compound. In cases in which the active agents have unsaturated carbon-carbon double bonds, both the cis (Z) and trans (E) isomers are within the scope of this invention. In cases where the active agents exist in tautomeric forms, such as keto-enol tautomers, each tautomeric form is contemplated as being included within the invention. Amikacin, in one embodiment, is present in the pharmaceutical composition as amikacin base, or amikacin salt, for example, amikacin sulfate or amikacin disulfate. In one embodiment, a combination of one or more of the above aminoglycosides is used in the compositions, systems and methods described herein.

**[0056]** Disclosed herein is, in one aspect, a method for treating or providing prophylaxis against a pulmonary NTM infection. Treatment is achieved via delivery of a composition comprising a liposomal aminoglycoside composition by inhalation via nebulization of the

composition. In one embodiment, the composition comprises an aminoglycoside encapsulated in a plurality of liposomes, e.g., an aminoglycoside selected from one or more of the aminoglycosides of Tables 1 and/or 2, or a pharmaceutically acceptable salt thereof.

**[0057]** The pharmaceutical composition, as provided herein, is a liposomal dispersion comprising an aminoglycoside complexed to a liposome, e.g., an aminoglycoside encapsulated in a plurality of liposomes. The pharmaceutical composition is a dispersion comprising a "liposomal complexed aminoglycoside" or an "aminoglycoside encapsulated in a liposome." A "liposomal complexed aminoglycoside" includes embodiments where the aminoglycoside (or combination of aminoglycosides) is encapsulated in a liposome, and includes any form of aminoglycoside composition where at least about 1% by weight of the aminoglycoside is associated with the liposome either as part of a complex with a liposome, or as a liposome where the aminoglycoside may be in the aqueous phase or the hydrophobic bilayer phase or at the interfacial headgroup region of the liposomal bilayer.

**[0058]** In one embodiment, the lipid component of the liposome or plurality of liposomes comprises electrically neutral lipids, positively charged lipids, negatively charged lipids, or a combination thereof. In another embodiment, the lipid component comprises electrically neutral lipids. In a further embodiment, the lipid component consists essentially of electrically neutral lipids. In a further embodiment, the electrically neutral lipids comprise a sterol and a phospholipid. In a further embodiment the sterol is cholesterol and the phospholipid is a neutral phosphatidylcholine. In embodiments of the invention, the phosphatidylcholine is dipalmitoylphosphatidylcholine (DPPC).

**[0059]** As provided above, in embodiments disclosed herein the aminoglycoside or pharmaceutically acceptable salt thereof is encapsulated in a plurality of liposomes. In addition, the liposomal complexed aminoglycoside describes any composition, solution or suspension where at least about 1% by weight of the aminoglycoside is associated with the lipid either as part of a complex with the liposome, or as a liposome where the aminoglycoside may be in the aqueous phase or the hydrophobic bilayer phase or at the interfacial headgroup region of the liposomal bilayer. In one embodiment, prior to nebulization, at least about 5%, at least about 10%, at least about 20%, at least about 25%, at least about 50%, at least about 75%, at least about 80%, at least about 85%, at least about 90% or at least about 95% of the aminoglycoside in the composition is so associated. Association, in one embodiment, is measured by separation through a filter where lipid and lipid-associated drug is retained (*i.e.*, in the retentate) and free drug is in the filtrate.

**[0060]** The methods provided herein comprise administering to a patient in need thereof a composition comprising an aminoglycoside or pharmaceutically acceptable salt thereof encapsulated in a plurality of liposomes. One or more lipids can be used to form the plurality of liposomes. In one embodiment, the one or more lipids is synthetic, semi-synthetic or a naturally-occurring lipid, including a phospholipid, tocopherol, sterol, fatty acid, negatively-charged lipid, cationic lipid or a combination thereof. In one embodiment, the lipid component of the plurality of liposomes consists of electrically neutral lipids. In one embodiment, the lipid

component comprises DPPC and cholesterol.

**[0061]** In one embodiment, at least one phospholipid is present in the plurality of liposomes. The phospholipid, in one embodiment, is electrically net neutral. In one embodiment, the phospholipid is a phosphatidylcholine (PC), phosphatidylglycerol (PG), phosphatidylinositol (PI), phosphatidylserine (PS), phosphatidylethanolamine (PE), and phosphatidic acid (PA); the soya counterparts, soy phosphatidylcholine (SPC); SPG, SPS, SPI, SPE, and SPA; the hydrogenated egg and soya counterparts (e.g., HEPC, HSPC), phospholipids made up of ester linkages of fatty acids in the 2 and 3 of glycerol positions containing chains of 12 to 26 carbon atoms and different head groups in the 1 position of glycerol that include choline, glycerol, inositol, serine, ethanolamine, as well as the corresponding phosphatidic acids. The carbon chains on these fatty acids can be saturated or unsaturated, and the phospholipid may be made up of fatty acids of different chain lengths and different degrees of unsaturation.

**[0062]** In one embodiment, the lipid component of the plurality of liposomes includes dipalmitoylphosphatidylcholine (DPPC), a major constituent of naturally-occurring lung surfactant. In one embodiment, the lipid component of the plurality of liposomes comprises DPPC and cholesterol, or consists essentially of DPPC and cholesterol, or consists of DPPC and cholesterol. In an embodiment, the DPPC and cholesterol have a mole ratio in the range of from about 19:1 to about 1:1, or about 9:1 to about 1:1, or about 4:1 to about 1:1, or about 2:1 to about 1:1, or about 1.86:1 to about 1:1. In even a further embodiment of the disclosure, the DPPC and cholesterol have a mole ratio of about 2:1 or about 1:1.

**[0063]** Other examples of lipids for use with the methods and compositions described herein include, but are not limited to, dimyristoylphosphatidylcholine (DMPC), dimyristoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylcholine (DPPC), dipalmitoylphosphatidylglycerol (DPPG), distearoylphosphatidylcholine (DSPC), distearoylphosphatidylglycerol (DSPG), dioleoylphosphatidyl-ethanolamine (DOPE), mixed phospholipids such as palmitoylstearylphosphatidyl-choline (PSPC), and single acylated phospholipids, for example, mono-oleoyl-phosphatidylethanolamine (MOPE).

**[0064]** In one embodiment, the lipid component of the plurality of liposomes comprises a sterol. In a further embodiment, the at least one lipid component comprises a sterol and a phospholipid, or consists essentially of a sterol and a phospholipid, or consists of a sterol and a phospholipid (e.g., a neutral phosphatidylcholine such as DPPC). Sterols for use with the disclosure include, but are not limited to, cholesterol, esters of cholesterol including cholesterol hemi-succinate, salts of cholesterol including cholesterol hydrogen sulfate and cholesterol sulfate, ergosterol, esters of ergosterol including ergosterol hemi-succinate, salts of ergosterol including ergosterol hydrogen sulfate and ergosterol sulfate, lanosterol, esters of lanosterol including lanosterol hemi-succinate, salts of lanosterol including lanosterol hydrogen sulfate, lanosterol sulfate and tocopherols. The tocopherols can include tocopherols, esters of tocopherols including tocopherol hemi-succinates, salts of tocopherols including tocopherol hydrogen sulfates and tocopherol sulfates. The term "sterol compound" includes sterols, tocopherols and the like.

**[0065]** In one embodiment, at least one cationic lipid (positively charged lipid) is provided in the lipid component of the plurality of liposomes, present in the liposomal aminoglycoside compositions described herein, for use in the method of treating an NTM pulmonary infection in a patient in need thereof. Cationic lipids include but are not limited to ammonium salts of fatty acids, phospholids and glycerides. The fatty acids include fatty acids of carbon chain lengths of 12 to 26 carbon atoms that are either saturated or unsaturated. Some specific examples include, but are not limited to, myristylamine, palmitylamine, laurylamine and stearylamine, dilauroyl ethylphosphocholine (DLEP), dimyristoyl ethylphosphocholine (DMEP), dipalmitoyl ethylphosphocholine (DPEP) and distearoyl ethylphosphocholine (DSEP), N-(2,3-di-(9-(Z)-octadecenyl)-prop-1-yl-N,N,N-trimethylammonium chloride (DOTMA), 1,2-bis(oleoyloxy)-3-(trimethylammonio) propane (DOTAP), and combinations thereof.

**[0066]** In one embodiment, at least one anionic lipid (negatively charged lipid) is provided in the lipid component of the plurality of liposomes, present in the liposomal aminoglycoside compositions described herein, for use in the method of treating an NTM pulmonary infection in a patient in need thereof. The negatively-charged lipids which can be used include phosphatidyl-glycerols (PGs), phosphatidic acids (PAs), phosphatidylinositols (PIs) and the phosphatidyl serines (PSs). Examples include but are not limited to DMPG, DPPG, DSPG, DMPA, DPPA, DSPA, DMPI, DPPI, DSPI, DMPS, DPPS, DSPS and combinations thereof.

**[0067]** Without wishing to be bound by theory, phosphatidylcholines, such as DPPC, aid in the uptake of the aminoglycoside agent by the cells in the lung (e.g., the alveolar macrophages) and helps to maintain the aminoglycoside agent in the lung. The negatively charged lipids such as the PGs, PAs, PSs and PIs, in addition to reducing particle aggregation, are thought to play a role in the sustained activity characteristics of the inhalation composition as well as in the transport of the composition across the lung (transcytosis) for systemic uptake. The sterol compounds, without wishing to be bound by theory, are thought to affect the release characteristics of the composition.

**[0068]** Liposomes are completely closed lipid bilayer membranes containing an entrapped aqueous volume. Liposomes may be unilamellar vesicles (possessing a single membrane bilayer) or multilamellar vesicles (onion-like structures characterized by multiple membrane bilayers, each separated from the next by an aqueous layer) or a combination thereof. The bilayer is composed of two lipid monolayers having a hydrophobic "tail" region and a hydrophilic "head" region. The structure of the membrane bilayer is such that the hydrophobic (nonpolar) "tails" of the lipid monolayers orient toward the center of the bilayer while the hydrophilic "heads" orient towards the aqueous phase.

**[0069]** The lipid to aminoglycoside ratio by weight (weight ratios are also referred to herein as "lipid : aminoglycoside") in the pharmaceutical composition provided herein, in one embodiment, is 3:1 or less, 2.5:1.0 or less, 2:1 or less, 1.5:1 or less, 1:1 or less or 0.75:1 or less. In one embodiment, the lipid : aminoglycoside weight ratio in the composition provided herein is 0.7:1.0 or about 0.7:1.0 by weight. In another embodiment, the L:D ratio in liposomes



provided herein is 0.75:1 or less (by weight). In one embodiment, the lipid : aminoglycoside weight ratio (lipid to aminoglycoside weight ratio) is from about 0.10:1.0 to about 1.25:1.0, from about 0.25:1.0 to about 1.25:1.0, from about 0.50:1.0 to about 1.25:1.0 or from about 0.6:1 to about 1.25:1.0. In another embodiment, the lipid to aminoglycoside weight ratio is from about 0.1:1.0 to about 1.0:1.0, or from about 0.25:1.0 to about 1.0:1.0 or about 0.5:1 to 1:1.0.

**[0070]** The lipid to aminoglycoside weight ratio in the composition provided herein in another embodiment, is less than 3:1, less than 2.5:1.0, less than 2.0:1.0, less than 1.5:1.0, or less than 1.0:1.0. In a further embodiment, the lipid to aminoglycoside weight ratio is about 0.7:1.0 or less or about 0.7:1.0. In yet another embodiment, the lipid to aminoglycoside weight ratio is from about 0.5:1.0 to about 0.8:1.0.

**[0071]** In order to minimize dose volume and reduce patient dosing time, in one embodiment, it is important that liposomal entrapment of the aminoglycoside (e.g., the aminoglycoside amikacin) be highly efficient and that the lipid to aminoglycoside weight ratio be at as low a value as possible and/or practical while keeping the liposomes small enough to penetrate patient mucus and biofilms. In one embodiment, the L aminoglycoside weight ratio in the composition provided herein, i.e., the composition comprising an aminoglycoside encapsulated in a plurality of liposomes is 0.7:1.0, about 0.7:1.0 from about 0.5:1.0 to about 0.8:1.0 or from about 0.6:1.0 to about 0.8:1.0. In a further embodiment, the liposomes provided herein are small enough to effectively penetrate a bacterial biofilm. In even a further embodiment, the mean diameter of the plurality of liposomes, as measured by light scattering is from about 200 nm to about 400 nm, or from about 250 nm to about 400 nm, or from about 250 nm to about 300 nm, or from about 200 nm to about 300 nm. In even a further embodiment, the mean diameter of the plurality of liposomes, as measured by light scattering is from about 260 to about 280 nm.

**[0072]** In one embodiment, the liposomal compositions described herein are manufactured by one of the methods set forth in U.S. Patent Application Publication No. 2013/0330400 or U.S. Patent No. 7,718,189. Liposomes can be produced by a variety of methods (see, e.g., Cullis et al. (1987)). In one embodiment, one or more of the methods described in U.S. Patent Application Publication No. 2008/0089927 are used herein to produce the aminoglycoside encapsulated lipid compositions (liposomal dispersion). For example, in one embodiment, at least one lipid and an aminoglycoside are mixed with a coacervate (i.e., a separate liquid phase) to form the liposome composition. The coacervate can be formed prior to mixing with the lipid, during mixing with the lipid or after mixing with the lipid. Additionally, the coacervate can be a coacervate of the active agent.

**[0073]** In one embodiment, the liposomal dispersion is formed by dissolving one or more lipids in an organic solvent forming a lipid solution, and the aminoglycoside coacervate forms from mixing an aqueous solution of the aminoglycoside with the lipid solution. In a further embodiment, the organic solvent is ethanol. In embodiments of the invention, the lipid solution comprises a phospholipid and a sterol, e.g., DPPC and cholesterol.

**[0074]** In one embodiment, liposomes are produced by sonication, extrusion, homogenization, swelling, electro formation, inverted emulsion or a reverse evaporation method. Bangham's procedure (J. Mol. Biol. (1965)) produces ordinary multilamellar vesicles (MLVs). Lenk et al. (U.S. Patent Nos. 4,522,803, 5,030,453 and 5,169,637), Fountain et al. (U.S. Patent No. 4,588,578) and Cullis et al. (U.S. Patent No. 4,975,282) disclose methods for producing multilamellar liposomes having substantially equal interlamellar solute distribution in each of their aqueous compartments. Paphadjopoulos et al., U.S. Patent No. 4,235,871, discloses preparation of oligolamellar liposomes by reverse phase evaporation. Each of the methods is amenable for use with the present invention.

**[0075]** Unilamellar vesicles can be produced from MLVs by a number of techniques, for example, the extrusion techniques of U.S. Patent No. 5,008,050 and U.S. Patent No. 5,059,421. Sonication and homogenization can be so used to produce smaller unilamellar liposomes from larger liposomes (see, for example, Paphadjopoulos et al. (1968); Deamer and Uster (1983); and Chapman et al. (1968)).

**[0076]** The liposome preparation of Bangham et al. (J. Mol. Biol. 13, 1965, pp. 238-252) involves suspending phospholipids in an organic solvent which is then evaporated to dryness leaving a phospholipid film on the reaction vessel. Next, an appropriate amount of aqueous phase is added, the mixture is allowed to "swell," and the resulting liposomes which consist of multilamellar vesicles (MLVs) are dispersed by mechanical means. This preparation provides the basis for the development of the small sonicated unilamellar vesicles described by Paphadjopoulos et al. (Biochim. Biophys. Acta. 135, 1967, pp. 624-638), and large unilamellar vesicles.

**[0077]** Techniques for producing large unilamellar vesicles (LUVs), such as, reverse phase evaporation, infusion procedures, and detergent dilution, can be used to produce liposomes for use in the pharmaceutical compositions provided herein. A review of these and other methods for producing liposomes may be found in the text *Liposomes*, Marc Ostro, ed., Marcel Dekker, Inc., New York, 1983, Chapter 1. See also Szoka, Jr. et al., (Ann. Rev. Biophys. Bioeng. 9, 1980, p. 467).

**[0078]** Other techniques for making liposomes include those that form reverse-phase evaporation vesicles (REV), U.S. Patent No. 4,235,871. Another class of liposomes that may be used is characterized as having substantially equal lamellar solute distribution. This class of liposomes is denominated as stable plurilamellar vesicles (SPLV) as defined in U.S. Patent No. 4,522,803, and includes monophasic vesicles as described in U.S. Patent No. 4,588,578, and frozen and thawed multilamellar vesicles (FATMLV) as described above.

**[0079]** A variety of sterols and their water soluble derivatives such as cholesterol hemisuccinate have been used to form liposomes; see, e.g., U.S. Patent No. 4,721,612. Mayhew et al., PCT Publication No. WO 85/00968, described a method for reducing the toxicity of drugs by encapsulating them in liposomes comprising alpha-tocopherol and certain derivatives thereof. Also, a variety of tocopherols and their water soluble derivatives have been

used to form liposomes, see PCT Publication No. 87/02219.

**[0080]** The pharmaceutical composition, in one embodiment, pre-nebulization, comprises liposomes with a mean diameter, that is measured by a light scattering method, of approximately 0.01 microns to approximately 3.0 microns, for example, in the range about 0.2 to about 1.0 microns. In one embodiment, the mean diameter of the liposomes in the composition is about 200 nm to about 300 nm, about 210 nm to about 290 nm, about 220 nm to about 280 nm, about 230 nm to about 280 nm, about 240 nm to about 280 nm, about 250 nm to about 280 nm or about 260 nm to about 280 nm. The sustained activity profile of the liposomal product can be regulated by the nature of the lipid membrane and by inclusion of other excipients in the composition.

**[0081]** In one embodiment, the method described herein comprises administering a liposomal complexed aminoglycoside composition, e.g., a liposomal complexed amikacin (e.g., amikacin sulfate) composition to a patient in need thereof via inhalation, for example, via a nebulizer. In one embodiment, the amount of aminoglycoside provided in the composition is about 450 mg, about 500 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg or about 610 mg. In another embodiment, the amount of aminoglycoside provided in the composition is from about 500 mg to about 600 mg, or from about 500 mg to about 650 mg, or from about 525 mg to about 625 mg, or from about 550 mg to about 600 mg. In one embodiment, the amount of aminoglycoside administered to the subject is about 560 mg and is provided in an 8 mL composition. In one embodiment, the amount of aminoglycoside administered to the subject is about 590 mg and is provided in an 8 mL composition. In one embodiment, the amount of aminoglycoside administered to the subject is about 600 mg and is provided in an 8 mL composition. In one embodiment, the aminoglycoside is amikacin and the amount of amikacin provided in the composition is about 450 mg, about 500 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg or about 610 mg. In another embodiment, the aminoglycoside is amikacin and the amount of amikacin provided in the composition is from about 500 mg to about 650 mg, or from about 525 mg to about 625 mg, or from about 550 mg to about 600 mg. In one embodiment, the aminoglycoside is amikacin and the amount of amikacin administered to the subject is about 560 mg, and is provided in an 8 mL composition. In one embodiment, the aminoglycoside is amikacin and the amount of amikacin administered to the subject is about 590 mg, and is provided in an 8 mL composition. In one embodiment, the aminoglycoside is amikacin and the amount of aminoglycoside administered to the subject is about 600 mg and is provided in an 8 mL composition.

**[0082]** In one embodiment, the methods described herein are carried out via the use of a system comprising a liposomal complexed aminoglycoside composition, for example, a liposomal encapsulated amikacin composition (e.g., amikacin sulfate) and a nebulizer. In one embodiment, the liposomal aminoglycoside composition provided herein comprises about 60 mg/mL aminoglycoside, about 65 mg/mL aminoglycoside, about 70 mg/mL aminoglycoside, about 75 mg/mL aminoglycoside, about 80 mg/mL aminoglycoside, about 85 mg/mL aminoglycoside, or about 90 mg/mL aminoglycoside. In embodiments of the invention, the

aminoglycoside is amikacin, for example, as amikacin sulfate.

**[0083]** In embodiments of the NTM treatment methods described herein, the liposomal aminoglycoside composition is administered to a patient in need thereof once per day in a single dosing session. In a further embodiment, the composition is administered as an aerosol via a nebulizer. In other embodiments, the method comprises administering to a patient in need thereof one of the aminoglycoside compositions described herein every other day or every three days. In yet other embodiments, the method comprises administering to a patient in need thereof one of the aminoglycoside compositions described herein twice per day.

**[0084]** The methods provided herein, in embodiments of the disclosure, comprise administering to a patient in need thereof one of the compositions described herein (e.g., via a nebulizer) for an administration period comprising at least one 1 month, 2 months, 3 months, 4 months, 5 months or 6 months. In one embodiment, an administration period is followed by a period where no composition is administered (referred to as "off period"), which is followed by another administration period. The off period, in one embodiment is about 1 month, about 2 months, about 3 months, about four months, about five months or about 6 months.

**[0085]** In one embodiment of the disclosure, the administration period is from about 15 days to about 400 days, e.g., from about 45 days to about 300 days, or from about 45 days to about 270 days, or from about 80 days to about 200 days. In one embodiment, the administration period comprises administration of the composition to a patient in need thereof in a once daily dosing session.

**[0086]** In another embodiment, the NTM treatment method described herein comprises administration of a liposomal complexed aminoglycoside composition to a patient in need thereof via a once daily dosing session for an administration period. In embodiments of the disclosure, the administration period is from about 15 to about 275 days, or from about 20 to about 235 days, or from about 28 days to about 150 days. For example, the methods provided herein comprise administering to a patient in need thereof an aminoglycoside composition once per day in a single dosing session for an administration period of from about 15 to about 300 days, or from about 15 to about 250 days, or from about 15 to about 200 days, or from about 15 to about 150 days, or from about 15 to about 125 days or from about 15 to about 100 days. In another embodiment of the disclosure, the administration period is from about 50 days to about 200 days. During the administration period, in one embodiment of the disclosure, the patient in need thereof is administered the aminoglycoside composition via nebulization, and about 500 mg to about 1000 mg aminoglycoside is administered daily in a single dosing session, for example, about 500 mg aminoglycoside to about 700 mg aminoglycoside (e.g., about 590 mg aminoglycoside).

**[0087]** In one embodiment, an administration period is followed by an off period from about 15 to about 200 days, for example, from about 15 days to about 150 days, or from about 15 days to about 75 days, from about 15 days to about 35 days, or from about 20 days to about 35 days, or from about 25 days to about 75 days, or from about 35 days to about 75 days or from

about 45 days to about 75 days. In another embodiment, the off period is about 28 days or about 56 days. In other embodiments, the off period is about 50, 51, 52, 53, 54, 55, 56, 57, 58, 59 or 60 days, while in other embodiments, the off period is about 56 days.

**[0088]** In one embodiment, the patient in need thereof is administered the liposomal complexed aminoglycoside composition in a treatment cycle comprising an administration period and an off period. In a further embodiment, the treatment cycle is implemented at least once. In a further embodiment, the treatment cycle is repeated at least twice, for example, two, three, four, five, six, seven, eight, nine or ten times. In another embodiment, the treatment cycle is repeated at least three times, for example, at least three, at least four, at least five or at least six times.

**[0089]** Various treatment cycles for patients with NTM lung infections are provided in Table 3, below. However, in another embodiment, the method provided herein does not comprise an off period and instead includes only an administration period. In an embodiment of the disclosure, one of the administration periods set forth in Table 3 is used in the method provided herein. In a further embodiment, the patient is administered the liposomal aminoglycoside composition once daily during the administration period in a single dosing session.

<b>Table 3. Treatment cycles of the present disclosure</b>			
Administration period	Off period	Treatment cycle(s)	Composition
15 to 500 days	15 to 75 days	At least once	Amikacin (500 mg-600 mg), DPPC, cholesterol, (lipid to aminoglycoside ratio by weight of 0.75:1 or less, e.g., 0.1:1.0 to about 1.25:1.0)
15 to 450 days	15 to 75 days	At least once	Amikacin (500 mg-600 mg), DPPC, cholesterol, (lipid to aminoglycoside ratio by weight of 0.75:1 or less, e.g., 0.1:1.0 to about 1.25:1.0)
15 to 400 days	15 to 75 days	At least once	Amikacin (500 mg-600 mg), DPPC, cholesterol, (lipid to aminoglycoside ratio by weight of 0.75:1 or less, e.g., 0.1:1.0 to about 1.25:1.0)
15 to 350 days	15 to 75 days	At least once	Amikacin (500 mg-600 mg), DPPC, cholesterol, (lipid to aminoglycoside ratio by weight of 0.75:1 or less, e.g., 0.1:1.0 to about 1.25:1.0)
15 to 325 days	15 to 75 days	At least once	Amikacin (500 mg-600 mg), DPPC, cholesterol, (lipid to aminoglycoside ratio by weight of 0.75:1 or less, e.g., 0.1:1.0 to about 1.25:1.0)
15 to 300 days	15 to 75 days	At least once	Amikacin (500 mg-600 mg), DPPC, cholesterol, (lipid to aminoglycoside ratio by weight of 0.75:1 or less, e.g., 0.1:1.0 to about 1.25:1.0)
15 to 275 days	15 to 75 days	At least once	Amikacin (500 mg-600 mg), DPPC, cholesterol, (lipid to aminoglycoside ratio by weight of 0.75:1 or less, e.g., 0.1:1.0 to about 1.25:1.0)
15 to 255 days	15 to 75	At least once	Amikacin (500 mg-600 mg), DPPC, cholesterol, (lipid to aminoglycoside ratio by weight of 0.75:1

<b>Table 3. Treatment cycles of the present disclosure</b>			
Administration period	Off period	Treatment cycle(s)	Composition
	days		or less, e.g., 0.1:1.0 to about 1.25:1.0)
15 to 225 days	15 to 75 days	At least once	Amikacin (500 mg-600 mg), DPPC, cholesterol, (lipid to aminoglycoside ratio by weight of 0.75:1 or less, e.g., 0.1:1.0 to about 1.25:1.0)
15 to 200 days	15 to 75 days	At least once	Amikacin (500 mg-600 mg), DPPC, cholesterol, (lipid to aminoglycoside ratio by weight of 0.75:1 or less, e.g., 0.1:1.0 to about 1.25:1.0)
15 to 175 days	15 to 75 days	At least once	Amikacin (500 mg-600 mg), DPPC, cholesterol, (lipid to aminoglycoside ratio by weight of 0.75:1 or less, e.g., 0.1:1.0 to about 1.25:1.0)
15 to 150 days	15 to 75 days	At least once	Amikacin (500 mg-600 mg), DPPC, cholesterol, (lipid to aminoglycoside ratio by weight of 0.75:1 or less, e.g., 0.1:1.0 to about 1.25:1.0)
15 to 125 days	15 to 75 days	At least once	Amikacin (500 mg-600 mg), DPPC, cholesterol, (lipid to aminoglycoside ratio by weight of 0.75:1 or less, e.g., 0.1:1.0 to about 1.25:1.0)
15 to 100 days	15 to 75 days	At least once	Amikacin (about 590 mg), DPPC, cholesterol, (L:D by weight of about 0.7:1)
15 to 75 days	15 to 75 days	At least once	Amikacin (about 590 mg), DPPC, cholesterol, (L:D by weight of about 0.7:1)
15 to 50 days	15 to 75 days	At least once	Amikacin (about 590 mg), DPPC, cholesterol, (L:D by weight of about 0.7:1)
20 to 100 days	15 to 75 days	At least once	Amikacin (about 590 mg), DPPC, cholesterol, (L:D by weight of about 0.7:1)

**[0090]** In one embodiment, the system provided herein comprises an about 8 mL liposomal amikacin composition and a nebulizer. In one embodiment, the density of the liposomal amikacin composition is about 1.05 gram/mL; and in one embodiment, approximately 8.4 grams of the liposomal amikacin composition per dose is present in the composition. In a further embodiment, the entire volume of the composition is administered to a subject in need thereof.

**[0091]** In one embodiment, the pharmaceutical composition provided herein comprises at least one aminoglycoside, at least one phospholipid and a sterol. In a further embodiment, the pharmaceutical composition comprises an aminoglycoside, DPPC and cholesterol. In one embodiment, the pharmaceutical composition is the composition provided in Table 4, below.

<b>Table 4. Pharmaceutical Compositions</b>			
<u>Composition A (pH 6.0-7.0)</u>		<u>Composition D (pH ~6.5)</u>	
<b>Component</b>	<b>Concentration</b>	<b>Component</b>	<b>Concentration</b>
Aminoglycoside	60-80 mg/mL	Aminoglycoside	~ 70 mg/mL
Phospholipid	30-40 mg/mL	Phospholipid	~ 32-35 mg/mL
Sterol	10-20 mg/mL	Sterol	~ 16-17 mg/mL
Salt	0.5%-5.0%	Salt	~ 1.5%
<u>Composition B (pH 6.0-7.0)</u>		<u>Composition E (pH ~6.5)</u>	
Amikacin Sulfate	60-80 mg/mL	Amikacin Sulfate	~ 70 mg/mL
DPPC	30-40 mg/mL	DPPC	~ 32-35 mg/mL
<b>Table 4. Pharmaceutical Compositions</b>			
Cholesterol	10-20 mg/mL	Cholesterol	~ 16-17 mg/mL
NaCl	0.5%-5.0%	NaCl	~ 1.5%
<u>Composition C (pH 6.0-7.0)</u>		<u>Composition F (pH ~6.5)</u>	
Amikacin Sulfate	70-80 mg/mL	Amikacin Sulfate	~ 70 mg/mL
DPPC	35-40 mg/mL	DPPC	~ 30-35 mg/mL
Cholesterol	15-20 mg/mL	Cholesterol	~ 15-17 mg/mL
NaCl	0.5%-5.0%	NaCl	~ 1.5%

**[0092]** It should be noted that increasing aminoglycoside concentration alone may not result in a reduced dosing time. For example, in one embodiment, the lipid to drug ratio is fixed, and as amikacin concentration is increased (and therefore lipid concentration is increased, since the ratio of the two is fixed, for example at ~0.7:1 by weight), the viscosity of the solution also increases, which slows nebulization time.

**[0093]** As provided throughout, the methods described herein comprise administering to a patient in need of treatment of an NTM lung infection, an effective amount of a liposomal aminoglycoside composition via inhalation. In one embodiment, inhalation delivery is conducted via a nebulizer. The nebulizer provides an aerosol mist of the composition for delivery to the lungs of the patient.

**[0094]** In one embodiment, the system provided herein comprises a nebulizer selected from an electronic mesh nebulizer, pneumatic (jet) nebulizer, ultrasonic nebulizer, breath-enhanced nebulizer and breath-actuated nebulizer. In one embodiment, the nebulizer is portable.

**[0095]** In one embodiment, the method for treating an NTM infection is carried out via administration of a liposomal complexed aminoglycoside composition to a patient in need

thereof via a nebulizer in once daily dosing sessions. In embodiments of the invention, the aminoglycoside is amikacin, e.g., amikacin sulfate. In embodiments of the invention, the lipid component of the liposomes consists of DPPC and cholesterol. In an embodiment, the nebulizer is one of the nebulizers described in U.S. Patent Application Publication No. 2013/0330400.

**[0096]** The principle of operation of a pneumatic nebulizer is generally known to those of ordinary skill in the art and is described, e.g., in Respiratory Care, Vol. 45, No. 6, pp. 609-622 (2000). Briefly, a pressurized gas supply is used as the driving force for liquid atomization in a pneumatic nebulizer. Compressed gas is delivered, which causes a region of negative pressure. The solution to be aerosolized is then delivered into the gas stream and is sheared into a liquid film. This film is unstable and breaks into droplets because of surface tension forces. Smaller particles, *i.e.*, particles with the MMAD and FPF properties described above, can then be formed by placing a baffle in the aerosol stream. In one pneumatic nebulizer embodiment, gas and solution is mixed prior to leaving the exit port (nozzle) and interacting with the baffle. In another embodiment, mixing does not take place until the liquid and gas leave the exit port (nozzle). In one embodiment, the gas is air, O<sub>2</sub> and/or CO<sub>2</sub>.

**[0097]** In one embodiment, droplet size and output rate can be tailored in a pneumatic nebulizer. However, consideration should be paid to the composition being nebulized, and whether the properties of the composition (e.g., % associated aminoglycoside) are altered due to the modification of the nebulizer. For example, in one embodiment, the gas velocity and/or pharmaceutical composition velocity is modified to achieve the output rate and droplet sizes. Additionally or alternatively, the flow rate of the gas and/or solution can be tailored to achieve the droplet size and output rate. For example, an increase in gas velocity, in one embodiment, decreased droplet size. In one embodiment, the ratio of pharmaceutical composition flow to gas flow is tailored to achieve the droplet size and output rate. In one embodiment, an increase in the ratio of liquid to gas flow increases particle size.

**[0098]** In one embodiment, a pneumatic nebulizer output rate is increased by increasing the fill volume in the liquid reservoir. Without wishing to be bound by theory, the increase in output rate may be due to a reduction of dead volume in the nebulizer. Nebulization time, in one embodiment, is reduced by increasing the flow to power the nebulizer. See, e.g., Clay et al. (1983). Lancet 2, pp. 592-594 and Hess et al. (1996). Chest 110, pp. 498-505.

**[0099]** In one embodiment, a reservoir bag is used to capture aerosol during the nebulization process, and the aerosol is subsequently provided to the subject via inhalation. In another embodiment, the nebulizer provided herein includes a valved open-vent design. In this embodiment, when the patient inhales through the nebulizer, nebulizer output is increased. During the expiratory phase, a one-way valve diverts patient flow away from the nebulizer chamber.

**[0100]** In one embodiment, the nebulizer provided herein is a continuous nebulizer. In other words, refilling the nebulizer with the pharmaceutical composition while administering a dose is



not needed. Rather, the nebulizer has at least an 8 mL capacity or at least a 10 mL capacity.

**[0101]** In one embodiment, the nebulizer provided herein does not use an air compressor and therefore does not generate an air flow. In one embodiment, aerosol is produced by the aerosol head which enters the mixing chamber of the device. When the patient inhales, air enters the mixing chamber via one-way inhalation valves in the back of the mixing chamber and carries the aerosol through the mouthpiece to the patient. On exhalation, the patient's breath flows through the one-way exhalation valve on the mouthpiece of the device. In one embodiment, the nebulizer continues to generate aerosol into the mixing chamber which is then drawn in by the subject on the next breath -- and this cycle continues until the nebulizer medication reservoir is empty.

**[0102]** In one embodiment, the nebulization time of an effective amount of an aminoglycoside composition provided herein is less than 20 minutes, less than 18 minutes, less than 16 minutes or less than 15 minutes. In one embodiment, the nebulization time of an effective amount of an aminoglycoside composition provided herein is less than 15 minutes or less than 13 minutes. In one embodiment, the nebulization time of an effective amount of an aminoglycoside composition provided herein is about 13 minutes.

**[0103]** In one embodiment, the composition described herein is administered once daily to a patient in need thereof.

**[0104]** In another embodiment, a patient is treated for an NTM lung infection with one of the methods and/or compositions provided herein. In embodiments of the invention, the composition comprises a liposomal amikacin composition. In a further embodiment, the composition comprises from about 500 mg to about 600 mg amikacin, DPPC and cholesterol, and the lipid to aminoglycoside weight ratio of the composition is 0.75:1.0 or less, e.g., about 0.7:1.0 or about 0.5:1.0 to about 0.8:1.0.

**[0105]** In one embodiment, the patient subjected to one of the treatment methods provided herein is a patient that was previously non-responsive to a different NTM treatment. In an embodiment of the disclosure, the composition administered to the patient in need of treatment is one of the compositions set forth in Table 4, above.

**[0106]** In one embodiment, prior to nebulization of the aminoglycoside composition, about 70% to about 100% of the aminoglycoside present in the composition is liposomal complexed. In embodiments of the invention, the aminoglycoside is amikacin. In an embodiment, prior to nebulization, about 80% to about 99%, or about 85% to about 99%, or about 90% to about 99% or about 95% to about 99% or about 96% to about 99% of the aminoglycoside present in the composition is liposomal complexed. In an embodiment of the disclosure, the aminoglycoside is amikacin or tobramycin. In embodiments of the invention, the aminoglycoside is amikacin. In an embodiment, prior to nebulization, about 98% of the aminoglycoside present in the composition is liposomal complexed. In an embodiment of the disclosure, the aminoglycoside is amikacin or tobramycin. In embodiments of the invention, the

aminoglycoside is amikacin (e.g., as amikacin sulfate).

**[0107]** In one embodiment, upon nebulization, about 20% to about 50% of the liposomal complexed aminoglycoside agent is released, due to shear stress on the liposomes. In embodiments of the invention, the aminoglycoside agent is an amikacin. In an embodiment, upon nebulization, about 25% to about 45%, or about 30% to about 40% of the liposomal complexed aminoglycoside agent is released from the liposomal complex, due to shear stress on the liposomes. In embodiments of the invention, the aminoglycoside agent is amikacin. In an embodiment, the amikacin is amikacin sulfate.

**[0108]** Upon nebulization of the composition described herein, i.e., for administration to a patient in need of treatment of an NTM infection, an aerosolized composition is formed, and in one embodiment, the mass median aerodynamic diameter (MMAD) of the aerosolized composition is about 1.0  $\mu\text{m}$  to about 4.2  $\mu\text{m}$  as measured by the Anderson Cascade Impactor (ACI). In one embodiment, the MMAD of the aerosolized composition is about 3.2  $\mu\text{m}$  to about 4.2  $\mu\text{m}$  as measured by the ACI. In one embodiment, the MMAD of the aerosolized composition is about 1.0  $\mu\text{m}$  to about 4.9  $\mu\text{m}$  as measured by the Next Generation Impactor (NGI). In a further embodiment, the MMAD of the aerosolized composition is about 4.4  $\mu\text{m}$  to about 4.9  $\mu\text{m}$  as measured by the NGI.

**[0109]** The fine particle fraction (FPF) of the aerosolized composition, in one embodiment, is greater than or equal to about 64%, as measured by the Anderson Cascade Impactor (ACI), or greater than or equal to about 51%, as measured by the Next Generation Impactor (NGI). In one embodiment, the FPF of the aerosolized composition is greater than or equal to about 70%, as measured by the ACI, greater than or equal to about 51%, as measured by the NGI, or greater than or equal to about 60%, as measured by the NGI.

**[0110]** Upon nebulization, the liposomes in the pharmaceutical composition leak drug. In one embodiment, the amount of liposomal complexed aminoglycoside post-nebulization is about 45% to about 85%, or about 50% to about 80% or about 51% to about 77%. These percentages are also referred to herein as "percent associated aminoglycoside post-nebulization." As provided herein, in embodiments of the invention, the liposomes comprise an aminoglycoside, e.g., amikacin. In one embodiment, the percent associated aminoglycoside post-nebulization is from about 60% to about 70%. In embodiments of the invention, the aminoglycoside is amikacin. In an embodiment, the percent associated aminoglycoside post-nebulization is about 67%, or about 65% to about 70%. In embodiments of the invention, the aminoglycoside is amikacin. In an embodiment, the amikacin is amikacin sulfate.

**[0111]** In one embodiment, the percent associated aminoglycoside post-nebulization is measured by reclaiming the aerosol from the air by condensation in a cold-trap, and the liquid is subsequently assayed for free and encapsulated aminoglycoside (associated aminoglycoside).

**[0112]** In another embodiment, the patient is a cystic fibrosis patient. In an embodiment of the

disclosure, the composition administered to the patient in need of treatment is one of the compositions set forth in Table 4, above.

**[0113]** In one embodiment, the patient in need of treatment of the NTM pulmonary infection is a bronchiectasis patient. In one embodiment, the bronchiectasis is non-Cystic Fibrosis (CF) bronchiectasis. In another embodiment, the bronchiectasis is associated with CF in a patient in need of treatment.

**[0114]** In another embodiment, the patient in need of treatment of the NTM pulmonary infection is a COPD patient. In yet another embodiment, the patient in need of treatment of the NTM pulmonary infection is an asthma patient. In an embodiment of the disclosure, the composition administered to the patient in need of treatment is one of the compositions set forth in Table 4, above.

**[0115]** In one embodiment, a patient in need of treatment with one of the methods described herein is a Cystic Fibrosis patient, a bronchiectasis patient, a ciliary dyskinesia patient, a chronic smoker, a chronic obstructive pulmonary disorder (COPD) patient, or a patient who has been previously non-responsive to treatment. In another embodiment, a cystic fibrosis patient is treated for an NTM pulmonary infection with one of the methods provided herein. In yet another embodiment, the patient is a bronchiectasis patient, a COPD patient or an asthma patient. The pulmonary NTM infection, in one embodiment of the disclosure, is MAC, *M. kansasii*, *M. abscessus*, or *M. fortuitum*. In embodiments of the invention, the pulmonary NTM infection is a MAC infection.

**[0116]** A patient subjected to the methods described herein, in one embodiment, has a comorbid condition. For example, in one embodiment, the patient in need of treatment with one of the methods described herein has diabetes, mitral valve disorder (e.g., mitral valve prolapse), acute bronchitis, pulmonary hypertension, pneumonia, asthma, trachea cancer, bronchus cancer, lung cancer, cystic fibrosis, pulmonary fibrosis, a larynx anomaly, a trachea anomaly, a bronchus anomaly, aspergillosis, HIV or bronchiectasis, in addition to the pulmonary NTM infection.

**[0117]** In one embodiment, a patient subjected to one of the NTM methods described herein exhibits an NTM culture conversion to negative during the administration period of the liposomal aminoglycoside composition, or after the administration period has concluded. The time to conversion, in one embodiment, is about 10 days, or about 20 days or about 30 days or about 40 days, or about 50 days, or about 60 days, or about 70 days, or about 80 days, or about 90 days, or about 100 days or about 110 days. In another embodiment, the time to conversion is from about 20 days to about 200 days, from about 20 days to about 190 days, from about 20 days to about 180 days, from about 20 days to about 160 days, from about 20 days to about 150 days, from about 20 days to about 140 days, from about 20 days to about 130 days, from about 20 days to about 120 days, from about 20 days to about 110 days, from about 30 days to about 110 days, or from about 30 days to about 100 days.

**[0118]** In some embodiments, the patient experiences an improvement in lung function for at least 15 days after the administration period ends, as compared to the FEV<sub>1</sub> of the patient prior to treatment. For example, the patient may experience an increase in FEV<sub>1</sub>, an increase in blood oxygen saturation, or both. In some embodiments, the patient has an FEV<sub>1</sub> (after the administration period or treatment cycle) that is increased by at least 5% over the FEV<sub>1</sub> prior to the administration period. In other embodiments, FEV<sub>1</sub> is increased by 5 to 50 % over the FEV<sub>1</sub> prior to the administration period. In other embodiments, FEV<sub>1</sub> is increased by 25 to 500 mL over FEV<sub>1</sub> prior to the administration period. In some embodiments, blood oxygen saturation is increased by at least 1% over oxygen saturation prior to the administration period.

**[0119]** In one embodiment, the 6-minute walk test (6MWT) is used to assess the effectiveness of the treatment methods provided herein. The 6MWT is used for the objective evaluation of functional exercise capacity and is a practical, simple test that measures the distance that a patient can walk in a period of 6 minutes (see American Thoracic Society. (2002). *Am J Respir Crit Care Med.* 166, pp. 111-117).

**[0120]** In one embodiment, a patient subjected to one of the NTM methods described herein exhibits an increased number of meters walked in the 6MWT, as compared to prior to undergoing the treatment method. The increased number of meters walked in the 6MWT, in one embodiment, is about 5 meters, about 10 meters, about 15 meters, about 20 meters, about 25 meters, about 30 meters, about 35 meters, about 40 meters, about 45 meters, or about 50 meters. In another embodiment, the increased number of meters walked in the 6MWT is at least about 5 meters, at least about 10 meters, at least about 15 meters, at least about 20 meters, at least about 25 meters, at least about 30 meters, at least about 35 meters, at least about 40 meters, at least about 45 meters, or at least about 50 meters. In yet another embodiment, the increased number of meters walked in the 6MWT is from about 5 meters to about 50 meters, or from about 5 meters to about 40 meters, or from about 5 meters to about 30 meters or from about 5 meters to about 25 meters.

**[0121]** In another embodiment, a patient subjected to one of the NTM methods described herein exhibits a greater number of meters walked in the 6MWT, as compared to a patient undergoing a non-liposomal aminoglycoside treatment. The greater number of meters walked in the 6MWT, as compared to a patient undergoing a non-liposomal aminoglycoside treatment, in one embodiment, is about 5 meters, about 10 meters, about 15 meters, about 20 meters, about 25 meters, about 30 meters, about 35 meters, about 40 meters, about 45 meters, about 50 meters, about 60 meters, about 70 meters or about 80 meters. In another embodiment, the greater number of meters walked in the 6MWT is at least about 5 meters, at least about 10 meters, at least about 15 meters, at least about 20 meters, at least about 25 meters, at least about 30 meters, at least about 35 meters, at least about 40 meters, at least about 45 meters, or at least about 50 meters. In yet another embodiment, the greater number of meters walked in the 6MWT is from about 5 meters to about 80 meters, or from about 5 meters to about 70 meters, or from about 5 meters to about 60 meters or from about 5 meters to about 50 meters.

**[0122]** In one embodiment, the liposomal aminoglycoside composition provided herein is administered to a patient in need of treatment of an NTM lung disease with an additional therapy.

**[0123]** In one embodiment, the liposomal aminoglycoside composition provided herein is administered to a patient in need of treatment of an NTM lung disease with one or more additional therapeutic agents. The one or more additional therapeutics agents in one embodiment of the disclosure, is administered orally. In another embodiment, of the disclosure the one or more additional therapeutics agents in one embodiment, is administered intravenously. In another embodiment, the one or more additional therapeutics agents is administered via inhalation.

**[0124]** The one or more additional therapeutic agents in one embodiment, is a macrolide antibiotic. In a further embodiment, the macrolide antibiotic is azithromycin, clarithromycin, erythromycin, carbomycin A, josamycin, kitamycin, midecamycin, oleandomycin, solithromycin, spiramycin, troleandomycin, tylosin, roxithromycin, or a combination thereof. In a further embodiment, the macrolide antibiotic is administered orally.

**[0125]** In one embodiment, the one or more additional therapeutic agents is the macrolide antibiotic azithromycin, clarithromycin, erythromycin, or a combination thereof. In a further embodiment, the macrolide antibiotic is administered orally.

**[0126]** In another embodiment, the liposomal aminoglycoside composition provided herein is administered to a patient in need of treatment of an NTM lung disease with one or more additional therapeutic agents, and the one or more additional therapeutic agents is a rifamycin compound. In a further embodiment, the rifamycin is rifampin. In another embodiment, the rifamycin is rifabutin, rifapentine, rifaximin, or a combination thereof.

**[0127]** In yet embodiment, the one or more additional therapeutic agents is a quinolone. In a further embodiment, the quinolone is a fluoroquinolone. In another embodiment, the quinolone is ciprofloxacin, levofloxacin, gatifloxacin, enoxacin, levofloxacin, ofloxacin, moxifloxacin, trovafloxacin, or a combination thereof.

**[0128]** In one embodiment, a second therapeutic agent is administered to the patient in need of NTM treatment, and the second therapeutic agent is a second aminoglycoside. In a further embodiment, the second aminoglycoside is amikacin, apramycin, arbekacin, astromicin, bekanamycin, boholmycin, brulamycin, capreomycin, dibekacin, dactimicin, etimicin, framycetin, gentamicin, H107, hygromycin, hygromycin B, inosamycin, K-4619, isepamicin, KA-5685, kanamycin, neomycin, netilmicin, paromomycin, plazomicin, ribostamycin, sisomicin, rhodestreptomycin, sorbistin, spectinomycin, sporaricin, streptomycin, tobramycin, verdamicin, vertilmicin, a pharmaceutically acceptable salt thereof, or a combination thereof. In a further embodiment, the second aminoglycoside is administered intravenously or via inhalation. In one embodiment the second aminoglycoside is streptomycin.

[0129] In another embodiment, the liposomal aminoglycoside composition provided herein is administered to a patient in need of treatment of an NTM lung disease with one or more additional therapeutic agents, and the one or more additional therapeutic agents is ethambutol, isoniazid, cefoxitin or imipenem.

### **EXAMPLES**

[0130] The present invention is further illustrated by reference to the following Examples. However, it should be noted that these Examples, like the embodiments described above, are illustrative and are not to be construed as restricting the scope of the invention in any way.

#### **Example 1: Randomized-double blind study of liposomal amikacin for inhalation (LAI) in patients with non-tuberculous mycobacterium (NTM) lung disease (LD)**

[0131] The increasing prevalence of NTM-LD is a public health concern and its management, particularly in cystic fibrosis patients, is complicated by prolonged use of multidrug regimens, drug toxicity, and poor response rates. LAI (also referred to herein as "Arikayce™" or "ARIKAYCE™") is a sustained-release lipid composition of amikacin in development for treatment of patients with recalcitrant NTM lung disease. This study evaluated the efficacy, safety, and tolerability of LAI in these patients in a randomized, double-blind (DB) study, conducted at 19 centers in North America. **Figure 1** is a flow chart showing the study design and **Figure 2** shows the patient distribution for the study.

[0132] The LAI composition had the following components:

<b>LAI composition</b>	
Amikacin Sulfate	~ 70 mg/mL
DPPC	~ 30-35 mg/mL
Cholesterol	~ 15-17 mg/mL
NaCl	~ 1.5%

[0133] Eligible NTM patients on a stable drug regimen were stratified based on presence or absence of cystic fibrosis (CF), and *Mycobacterium avium complex (MAC) versus Mycobacterium abscessus (M. abscessus)* lung disease, and randomized 1:1 to receive either once daily 590 mg LAI or placebo via eFlow® nebulizer system (PARI Pharma GmbH) for 84 days added to their ongoing stable drug regimen. **Figure 3** shows the number of patients in each group (randomized per strata). Patients were eligible for enrollment if they had pulmonary NTM infection refractory to American Thoracic Society / Infectious Disease Society of America (ATS/IDSA) guideline-based therapy for ≥6 months prior to screening.

[0134] After completing the double blind (DB) phase, patients who consented to the open-label (OL) phase received LAI 590 mg once daily, for 84 more days (**Figures 1 and 2**).

[0135] Of 136 screened patients, 90 were randomized (19% CF; 81% non-CF; 64% with MAC and 36% with *M abscessus*). 54% of patients were >60 years of age; 31% were >40-60 years, and 14% were 18-40 years. The baseline mean age was 58.5 years (standard deviation, 15.83 years).

[0136] The study is complete, with 80 and 59 patients having completed the DB and OL phases, respectively. Demographics and baseline characteristics of the mITT population are provided below in Table 5.

<b>Table 5. Demographics and Baseline Characteristics of mITT Population</b>			
	LAI (n=44)	Placebo (n = 45)	Overall (n - 89)
Gender, n (%)			
Male	6 (13.6)	5(11.1)	11 (12.4)
Female	38 (86.4)	40 (88.9)	78 (87.6)
Race/Ethnicity, n (%)			
Caucasian (not of Hispanic Origin)	42 (95.5)	40 (88.9)	82 (92.1)
Hispanic	0	2 (4.4)	2 (2.2)
African	0	1(2.2)	1(1.1)
Asian	2 (4.5)	2 (4.4)	4(4.5)
Other	0	0	0
Baseline Age, years			
n	44	45	89
Mean (SD)	58.0 (16.61)	59.1 (15.20)	58.5 (15.83)
Median	61.5	63.0	63.0
Min, Max	18, 85	19, 80	18, 85
Baseline FEV <sub>1</sub> Percent Predicted			
n	44	45	89
Mean (SD)	65.56 (21.339)	62.56 (17.168)	63.06 (19.239)
Median	61.25	61.00	61.00
Min, Max	30.2,114.9	34.4, 101.6	30.2, 114.9

**[0137]** The sample population enrolled in the mITT study exhibited the following: (1) comorbid lung disease, with 17 of the patients having cystic fibrosis; (2) a mean age of 59 years, including the younger cystic fibrosis patients; (3) lung abnormalities including 68 patients with cavitory lesions, and 21 patients with nodular disease which further includes minimal cavitory disease; (4) a mean body mass index (BMI) of 21.98, whereas comparable CDC data collected from between 2007 and 2010 reveals U.S average BMI of adult males to be 28.6 and adult females to be 28.7; and (5) an average baseline of ~441 m for all patients, with both arms having approximately the same mean baseline six-minute walk distance.

**[0138]** Sputum for semi-quantitative mycobacterial culture, smear status, signs/symptoms, pulmonary exacerbation occurrence, antimycobacterial drug rescue, six-minute walk distance (6MWD), computed tomography of the chest, spirometry, clinical/laboratory safety parameters, and quality of life measures were evaluated every 28 days. The primary endpoint was change from baseline on the semi-quantitative scale for mycobacterial culture; a secondary endpoint was the proportion of patients with NTM culture conversion to negative for LAI vs placebo at Day 84. All patients had a safety follow-up visit 28 days after the last dose of study drug, up to Day 196 for those in the OL phase.

**[0139]** **Figure 4** is a graph showing the mean change from baseline on the full semi quantitative scale for mycobacterial culture (mITT population) as a function of study day in both the double-blind phase and the open-label phase of the study. As shown in the figure, patients treated with LAI showed at least a one-step reduction in the treatment arm versus the placebo arm in the double-blind phase.

**[0140]** The proportion of patients with negative sputum cultures for NTM in each subgroup by treatment arm at Day 84 and Day 168 (mITT population) are summarized in Tables 6-8. At Day 84, statistically significant between-group differences in patients achieving negative sputum cultures for NTM, in favor of LAI vs. placebo, were seen in patients with non-CF infection ( $P = .01$ ), MAC infection ( $P = .017$ ), females ( $P = .004$ ), Caucasians ( $P = .031$ ), and patients aged <63 years ( $P = .041$ ) (Table 6).

**[0141]** At Day 168, statistically significantly more patients with MAC infection in the prior LAI arm vs. prior placebo arm had negative sputum cultures for NTM ( $P = .026$ ) (Table 6). In subgroup analyses (Table 7 and Table 8) of patients with NTM lung infection refractory to guideline-based therapy, LAI appeared superior to placebo with regard to negative sputum cultures for NTM in patients with non-CF underlying lung disease and MAC infection. The subgroup of patients with non-CF MAC infection demonstrated a positive efficacy result within the timeframe of the study (*i.e.*, 12-week double-blind phase and 12-week open-label phase)

**[0142]** Time to culture conversion showed statistically significantly greater proportion of patients in the LAI arm becoming culture negative at all visits in the double blind phase (Days 28, 56, and 84) (**Figure 5 top**). Specifically, LAI achieved statistical significance in achieving a



negative culture at Day 84, with 11 of 44 patients on LAI versus 3 of 45 patients on placebo ( $P = .01$ ) (**Figure 5 top**). Compared with placebo, LAI demonstrated statistical significance with regard to the proportion of patients with MAC infections who achieved culture negativity at Day 56 (LAI, 10/29 patients vs. placebo, 2/28 patients;  $P = .0144$ ) and at Day 84 (LAI, 10/29 patients vs. placebo, 3/28 patients;  $P = .0273$ ) (**Figure 5 bottom**).

[0143] In patients refractory to NTM-regimens for at least 6 months, LAI, an inhaled amikacin composition, lead to significantly greater culture conversion compared to placebo within 84 days. Patients with at least one NTM culture negative result are provided in **Figure 6**.

**Table 6. Proportion of Patients with negative sputum cultures for NTM in each subgroup by treatment arm at days 84 and 168 (mITT population)<sup>a</sup>**

Subgroups, n/n (%)	Day 84 (double-blind phase)			Day 168 (open-label phase)		
	LAI	Placebo	$P$ value <sup>b</sup>	Prior LAI <sup>c</sup>	Prior placebo <sup>c</sup>	$P$ value <sup>b</sup>
	(n = 44)	(n = 45)		(n = 35)	(n = 43)	
<b>Infection type</b>						
<b>MAC</b>	10/27 (37.0)	3/28 (10.7)	<b>.017</b>	12/24 (50.0)	6/27 (22.2)	<b>.026</b>
<b>MAB</b>	1/14 (7.1)	0/17	.317	1/11 (9.1)	2/14 (14.3)	.691
<b>CF</b>	0/7	0/9	NA	1/6 (16.7)	0/7	.221
<b>Non-CF</b>	11/34 (32.4)	3/36 (8.3)	<b>.01</b>	12/29 (41.4)	8/34 (23.5)	.122
<b>Gender</b>						
<b>Female</b>	11/36 (30.60)	2/40 (5.0)	<b>.004</b>	12/31 (38.7)	8/36 (22.2)	.137
<b>Male</b>	0/5	1/5 (20.0)	.414	1/4 (25.0)	0/5	.480
<b>Ethnicity</b>						
<b>Caucasian</b>	10/39 (25.6)	3/40 (7.5)	<b>.031</b>	13/33 (39.4)	8/37 (21.6)	.107
<b>Non-Caucasian</b>	1/2 (50.0)	0/5	NA	0/2	0/4	N/A
<b>Age</b>						
<b>&lt;63 years</b>	7/21 (33.3)	2/22 (9.1)	<b>.041</b>	7/19 (36.8)	3/20 (15.0)	.098
<b>&gt;63 years</b>	4/20 (20.0)	1/23 (4.3)	.108	6/16 (37.5)	5/21 (23.8)	.367

CF, cystic fibrosis; LAI, liposomal amikacin for inhalation; MAB, *Mycobacterium avium* complex; mITT, modified intent-to-treat; NTM, nontuberculous mycobacteria; NA, not available.

<sup>a</sup> Missing values are excluded under the assumption of missing at random, for which missing baseline or post-baseline values are excluded but all non-missing data are included (ie, exclusion is not at subject-level but, rather, at time point-level).

<sup>b</sup>For pairwise comparisons of the LAI arm with the placebo arm, a stratified Cochran-Mantel-Haenszel test of treatment arm adjusting for the randomization strata was used.

<sup>c</sup>All patients received LAI in the open-label phase.

**Table 7. Subgroup analysis of patients with MAC infection who achieved negative sputum cultures for NTM by treatment arm at days 84 and 168 168 (mITT population)<sup>a</sup>**

Subgroups, n/n (%)	Day 84 (double-blind phase)			Day 168 (open-label phase)		
	LAI	Placebo	<i>P</i> value <sup>b</sup>	Prior LAI <sup>c</sup>	Prior placebo <sup>c</sup>	<i>P</i> value <sup>b</sup>
	(n = 29)	(n = 28)		(n = 24)	(n = 28)	
<b>Infection type</b>						
<b>CF</b>	0/2	0/1	NA	0/2	0/1	N/A
<b>Non-CF</b>	10/25 (40.0)	3/27 (11.1)	<b>.025</b>	12/22 (54.6)	6/26 (23.1)	<b>.037</b>
<b>Cavitary disease</b>	5/17 (29.4)	2/20 (10.0)	.212	5/14 (35.7)	2/19 (10.5)	.106
<b>Non-cavitary disease</b>	5/10 (50.0)	1/8 (12.5)	.152	7/10 (70.0)	4/8 (50.0)	.631
<b>Gender</b>						
<b>Female</b>	10/25 (40.0)	2/25 (8.0)	<b>.018</b>	12/22 (54.6)	6/24 (25.0)	.069
<b>Male</b>	0/2	1/3 (33.3)	1.000	0/2	0/3	N/A
<b>Ethnicity</b>						
<b>Caucasian</b>	10/27 (37.0)	3/25 (12.0)	.055	12/24 (50.0)	6/24 (25.0)	.135
<b>Non-Caucasian</b>	0/0	0/3	NA	0/0	0/3	NA
<b>Age</b>						
<b>&lt;63 years</b>	6/13 (46.2)	2/11 (18.2)	.211	6/13 (46.2)	2/11 (18.2)	.211
<b>&gt;63 years</b>	4/14 (28.6)	1/17 (5.9)	.148	6/11 (54.6)	4/16 (25.0)	.224

CF, cystic fibrosis; LAI, liposomal amikacin for inhalation; MAC, *Mycobacterium avium* complex; mITT, modified intent-to-treat; NA, not available.

<sup>a</sup> Missing values are excluded under the assumption of missing at random, for

which missing baseline or post-baseline values are excluded but all non-missing data are included (ie, exclusion is not at subject-level but, rather, at time point-level).

<sup>b</sup> Pairwise comparisons of the LAI arm with the placebo arm were based on Fisher's Exact Test.

<sup>c</sup> All patients received LAI in the open-label phase.

**Table 8. Subgroup analysis of patients with *M. abscessus* (MAB) infection who achieved negative sputum cultures for NTM by treatment arm at days 84 and 168 168 (mITT population)<sup>3</sup>**

Subgroups, n/n (%)	Day 84 (double-blind phase)			Day 168 (open-label phase)		
	LAI	Placebo	<i>P</i> value <sup>b</sup>	Prior LAI <sup>c</sup>	Prior placebo <sup>c</sup>	<i>P</i> value <sup>b</sup>
	(n = 15)	(n = 17)		(n = 11)	(n = 15)	
<b>Infection type</b>						
CF	0/5	0/8	NA	1/4 (25.0)	0/6	.400
Non-CF	1/9 (11.1)	0/9	1.000	0/7	2/8 (25.0)	.467
Cavitary disease	1/13 (7.7)	0/15	.464	1/10 (10.0)	2/12 (16.7)	1.000
Non-cavitary disease	0/1	0/2	NA	0/1	0/2	N/A
<b>Gender</b>						
Female	1/11 (9.1)	0/15	.423	0/9	2/12 (16.7)	.486
Male	0/3	0/2	NA	1/2 (50.0)	0/2	1.000
<b>Ethnicity</b>						
Caucasian	0/12	0/15	NA	1/9 (11.1)	2/13 (15.4)	1.000
Non-Caucasian	1/2 (50.0)	0/2	1.000	0/2	0/1	NA
<b>Age</b>						
<63 years	1/8 (12.5)	0/11	.421	1/6 (16.7)	1/9 (11.1)	1.000
>63 years	0/6	0/6	NA	0/5	1/5 (20.0)	1.000

CF, cystic fibrosis; LAI, liposomal amikacin for inhalation; MAB, *Mycobacterium abscessus*; mITT, modified intent-to-treat; NA, not available.

<sup>a</sup> Missing values are excluded under the assumption of missing at random, for which missing baseline or post-baseline values are excluded but all non-missing data are included (ie, exclusion is not at subject-level but, rather, at time point-level).

<sup>b</sup> Pairwise comparisons of the LAI arm with the placebo arm were based on Fisher's Exact Test.

<sup>c</sup> All patients received LAI in the open-label phase.

---

[0144] The six-minute walk test (6MWT) assessed the impact of LAI on overall physical function or capacity. Results for the 6MWT endpoint (change from baseline from Day 1 to Day 84 at end of double blind study) are provided in **Figure 7** and **Figure 8**. LAI demonstrated statistical significance in the 6MWT in the double-blind phase (LAI vs placebo: 23.895 vs -25.032 meters,  $P=0.009$ ). The mean change from baseline to Day 84 in distance walked (meters) in the 6MWT was significantly higher for patients receiving LAI vs. placebo (20.64 m vs. -25.03 m) (**Figure 7 bottom**). In the open-label phase, patients in the LAI arm continued to improve on the 6MWT and patients in the placebo group who started LAI showed a dramatic decline in the rate of deterioration (**Figures 7 and 8**). Further, a significant difference was seen in the mean change from baseline to Day 168 in the 6MWT score for patients with sustained culture-negative status to the end of the open-label phase vs. those without sustained culture-negative status (55.75 m vs. -13.42 m) (**Figure 8 bottom**).

[0145] Patients with NTM lung infections refractory to treatment showed improvement in distance walked in the 6MWT when LAI was added to their background of guideline-based therapy. Patients with sustained culture-negative status during the study achieved better physical functional capacity as assessed by the 6MWT.

[0146] The sample population enrolled in the mITT study exhibited the following, prior to day 168, with regard to culture conversion, measured as three consecutive negative sputum cultures: (1) a total of 16 patients demonstrated culture conversion, all of which were non-cystic fibrosis; (2) 15 patients had MAC and 1 had *M. abscessus*; (3) 8 patients exhibited no treatment success despite greater than 24 months of non-LAI treatment methods, 4 patients exhibited no treatment success despite 12 to 24 months of non-LAI treatment methods, and 4 patients exhibited no treatment success despite 6 to 12 months of non-LAI treatment methods; (4) 7 patients exhibited nodular disease, 2 patients exhibited nodular disease and minimal cavitory lesions, and 7 patients exhibited cavitory lesions; (5) 11 patients started to convert at or prior to day 56 after beginning LAI treatment methods, 2 patients converted at day 84 after beginning LAI treatment methods, and 3 patients converted at day 112 after beginning LAI treatment methods; and (6) 6MWT for converters ( $n=16$ ) vs. nonconverters ( $n=43$ ) at day 168 was 89.34 meters (converters) vs. 3.85 meters (nonconverters), with a p-value of 0.0034.

[0147] No difference between arms in patients with hemoptysis, tinnitus, and hearing loss was found.

[0148] Moreover, it was found that patients entering the open label phase from LAI in the double blind phase (see **Figure 1** for study design) continued to improve. Additionally, patients entering open label phase from placebo demonstrate a dramatic decrease in their rate of decline. Most treatment emergent adverse events (TEAEs) were mild or moderate in severity, and the majority of TEAEs were respiratory in nature (Table 9). Local events and infective exacerbation of the underlying lung disease were the most common TEAEs. Few patients discontinued the study drug due to these events.

---

<b>Table 9. Overview of Adverse Events Through End of Open-label Phase (Safety Population)</b>				
	<b>Double Blind Phase<sup>a</sup></b>		<b>Open-Label Phase<sup>b</sup></b>	
	<b>LAI</b>	<b>Placebo</b>	<b>LAIC</b>	<b>Placebo<sup>c</sup></b>
	<b>(n = 44)</b>	<b>(n = 45)</b>	<b>(n = 35)</b>	<b>(n = 43)</b>
Subjects with treatment-emergent adverse events (TEAEs), n(%)	41 (93.2)	40 (88.9)	31 (88.6)	42 (97.7)
TEAEs, n	240	140	107	160
Subjects with TEAEs by maximum severity, n (%)				
Grade 1:Mild	12 (27.3)	25 (55.6)	16 (45.7)	10 (23.3)
Grade 2: Moderate	24 (54.5)	10 (22.2)	10 (28.6)	24 (55.8)
Grade 3:Severe	4 (9.1)	5(11.1)	4 (11.4)	8 (18.6)
Grade 4:Life-threatening or disabling	0	0	0	0
Grade 5:Death <sup>d</sup>	1 (2.3)	0	1 (2.9)	0
Subjects with TEAEs by seriousness, n (%)				
Serious	8 (18.2)	4 (8.9)	5 (14.3)	5 (11.6)
Not serious	33 (75.0)	36 (80.0)	26 (74.3)	37 (86.0)
Treatment-emergent serious adverse events, n	12	5	10	5
Subjects with TEAEs by relationship to study drug, n (%)				
Related	3 (6.8)	0	17 (48.6)	26 (60.5)
Not related	5 (11.4)	4 (8.9)	14 (40.0)	16 (37.2)
Subjects with treatment-emergent audiovestibular adverse events, n (%)	5 (11.4)	5 (11.1)	2 (5.7)	2 (4.7)
Subjects with treatment-emergent renal adverse events, n(%)	1 (2.3)	0	1 (2.9)	0
Subjects with adverse events leading to study drug discontinuation, n (%)	8 (18.2)	0	6 (17.1)	12 (27.9)

**Example 2: Study of Liposomal Amikacin for Inhalation (LAI) in Patients with Non-CF *M. avium* complex (MAC) Lung Infection**

[0149] LAI (also referred to herein as "Arikayce™" or "ARIKAYCE™") is a sustained-release lipid composition of amikacin in development for treatment of patients with recalcitrant NTM lung disease. In this study, the efficacy, safety, and tolerability of LAI is assessed in non-Cystic Fibrosis patients having *M. avium* complex (MAC) lung infection. **Figure 9** is a flow chart showing the study design.

[0150] The LAI composition has the following components:

LAI composition	
Amikacin Sulfate	~ 70 mg/mL
DPPC	~ 30-35 mg/mL
Cholesterol	~ 15-17 mg/mL
LAI composition	
NaCl	~ 1.5%

[0151] Table 10 provides the inclusion criteria for the study.

Table 10. Inclusion Criteria for Study
• Age ≥ 18 years ≤85 years
• Diagnosis of pulmonary NTM MAC lung disease
• Failed prior treatment
• Multi-drug regimen for at least 6 months; last dose within the prior 12 months

[0152] Patients are randomized 2:1 into two groups: (i) 590 mg LAI + background therapy and (ii) background therapy only). Each patient group is subjected to daily dosing for 8 months. Primary culture conversion is assessed at 6 months. 6MWT is also carried out for each patient at 6 months.

[0153] Culture converters continue treatment for 12 months post conversion.

## REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

### Patent documents cited in the description

- [US5756121A](#) [0008]
- [US2007077290A1](#) [0009]
- [US2009104256A1](#) [0010]
- [US2013136788A1](#) [0010]
- [US2004142026A1](#) [0011]
- [US4952405A](#) [0012]
- [US2013330400A1](#) [0013]
- [US2012192861A1](#) [0014]
- [US20130330400A](#) [0072] [0095]
- [US7718189B](#) [0072]
- [US20080089927A](#) [0072]
- [US4522803A](#) [0074] [0078]
- [US5030453A](#) [0074]
- [US5169637A](#) [0074]
- [US4588578A](#) [0074] [0078]
- [US4975282A](#) [0074]
- [US4235871A](#) [0074] [0078]
- [US5008050A](#) [0075]
- [US5059421A](#) [0075]
- [US4721612A](#) [0079]
- [WO8500968A](#) [0079]
- [WO8702219A](#) [0079]

#### Non-patent literature cited in the description

- **N DUZGUNES et al.** Treatment of intracellular Mycobacterium avium complex infection by free and liposome-encapsulated sparfloxacin *Antimicrobial Agents and Chemotherapy*, 1996, 2618-2621 [0006]
- **SASHA J. ROSE et al.** Delivery of Aerosolized Liposomal Amikacin as a Novel Approach for the Treatment of Nontuberculous Mycobacteria in an Experimental Model of Pulmonary Infection *PLOS ONE*, 2014, vol. 9, 9e108703- [0007]
- *Respiratory Care*, 2000, vol. 45, 6609-622 [0041] [0096]
- *J. Mol. Biol.*, 1965, [0074]
- **BANGHAM et al.** *J. Mol. Biol.*, 1965, vol. 13, 238-252 [0076]
- **PAPAHADJOPOULOS et al.** *Biochim. Biophys. Acta*, 1967, vol. 135, 624-638 [0076]
- *text Liposomes* Marcel Dekker, Inc. 19830000 [0077]
- **SZOKA, JR. et al.** *Ann. Rev. Biophys. Bioeng.*, 1980, vol. 9, 467- [0077]
- **CLAY et al.** *Lancet*, 1983, vol. 2, 592-594 [0098]
- **HESS et al.** *Chest*, 1996, vol. 110, 498-505 [0098]

- Am J Respir Crit Care Med.American Thoracic Society20020000vol. 166, 111-117 [\[0119\]](#)



**PATENTKRAV**

1. Farmaceutisk sammensætning, som omfatter fra 450 mg til 650 mg amikacin eller et farmaceutisk acceptabelt salt deraf indkapslet i en flerhed af liposomer, hvor  
5 lipidbestanddelen af flerheden af liposomer består af et dipalmitoylphosphatidylcholin (DPPC) og kolesterol, til anvendelse ved behandling eller tilvejebringelse af profylakse mod en *Mycobacterium avium*-kompleks (MAC)-lungeinfektion hos en patient med behov for behandling eller profylakse,  
hvor sammensætningen administreres én gang dagligt ved en enkeltdosering i en  
10 administrationsperiode på mindst tre måneder til patientens lunger ved at forstøve den farmaceutiske sammensætning via en nebulisator for at tilvejebringe en forstøvet farmaceutisk sammensætning, som omfatter en blanding af frit amikacin eller farmaceutisk acceptabelt salt deraf og liposomkompleksbundet amikacin eller farmaceutisk acceptabelt salt deraf,  
15 hvor patienten i løbet af administrationsperioden eller efter administrationsperioden oplever en MAC-dyrkningskonvertering til negativ.
2. Farmaceutisk sammensætning til anvendelse ifølge krav 1, hvor patienten i løbet af administrationsperioden eller efter administrationsperioden udviser et forøget antal  
20 gåede meter i 6-minutters gangtesten (6MWT, 6 minute walk test) sammenlignet med det antal meter, patienten gik inden udsættelse for behandlingsmetoden.
3. Farmaceutisk sammensætning til anvendelse ifølge krav 1 eller 2, hvor patienten oplever en forbedring i forceret eksspirationsvolumen på et sekund (FEV<sub>1</sub>) i mindst 15  
25 dage efter afslutningen af administrationsperioden sammenlignet med patientens FEV<sub>1</sub> inden behandlingen.
4. Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 1-3, hvor amikacinet eller det farmaceutisk acceptable salt deraf er amikacinsulfat.  
30
5. Farmaceutisk sammensætning til anvendelse ifølge krav 4, hvor liposomet omfatter unilamellare vesikler, multilamellare vesikler eller en blanding deraf.
6. Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 1-5, hvor det volumen af den farmaceutiske sammensætning, som administreres til  
35 patienten, er fra ca. 8 ml til ca. 10 ml.
7. Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 1-6,

hvor den forstøvede farmaceutiske sammensætning under enkeltdoseringen administreres på mindre end ca. 15 minutter, mindre end ca. 14 minutter, mindre end ca. 13 minutter, mindre end ca. 12 minutter eller mindre end ca. 11 minutter.

- 5     8.     Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 1-7, hvor patienten med behov for behandling eller profylakse tidligere ikke har reageret på MAC-behandling.
- 10     9.     Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 1-8, hvor det forøgede antal gæde meter i 6MWT er mindst ca. 5 meter.
- 15     10.     Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 3-9, hvor forbedringen i patientens FEV<sub>1</sub> er på mindst 5 % i forhold til patientens FEV<sub>1</sub> inden behandlingen.
- 20     11.     Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 1-10, hvor den farmaceutiske sammensætning omfatter fra ca. 550 mg til ca. 625 mg amikacin eller farmaceutisk acceptabelt salt deraf.
- 25     12.     Farmaceutisk sammensætning til anvendelse ifølge krav 11, hvor den farmaceutiske sammensætning omfatter fra ca. 550 mg til ca. 600 mg amikacin eller farmaceutisk acceptabelt salt deraf.
- 30     13.     Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 1-12, hvor patienten oplever en forbedring i blodets oxygenmætning i mindst 15 dage efter afslutningen af administrationsperioden sammenlignet med blodets oxygenmætning hos patienten inden administrationsperioden.
- 30     14.     Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 1-13, hvor administrationsperioden er på mindst ca. 6 måneder.

## DRAWINGS




FIGURE 2

## Patient Distribution




FIGURE 3





FIGURE 4

Change from Baseline on the Full Semi Quantitative Scale  
for Mycobacterial Culture (mITT Population)




LAI, liposomal amikacin for inhalation; mITT, modified intent-to-treat; SOC, standard of care.

<sup>a</sup>All patients in the open-label phase received LAI.

FIGURE 5

Proportion of Subjects with NTM Culture Conversion to Negative (mITT Population)



Proportion of Subjects with NTM Culture Conversion to Negative (MAC Population)




FIGURE 6

## Patients with at least 1 NTM Culture Negative Result

Treatment Arm	CF Patient	NTM Organism	Length of NTM Prior to Baseline (Months)	Prior Amikacin Use	SQS at Screening	Baseline	Day 28	Day 56	Day 84	Day 112	Day 140	Day 168	78-Day Follow up	
LAI	Non-CF	MAC	>24		2									
			>24		5									
			>24		5									
			>24		6									
			>24		2									
			>12 - 24		2									
			>12 - 24		2									
			>12 - 24	INH	3									
			>12 - 24		3									
			>12 - 24		3									
			6 - 12		3									
			6 - 12		4									
PBO	CF	M. abscessus	6 - 12		3									
		M. abscessus	>12 - 24	IV	5									
		M. abscessus	>12 - 24	INH	3									
		M. abscessus	>24	INH	3									
		M. abscessus	6 - 12	INH	6									
		M. abscessus	>24		4									
	Non-CF Patient	MAC	>24	INH	3									
			>24		3									
			>24		4									
			>12 - 24		4									
			>12 - 24		2									
			>12 - 24		3									
	M. abscessus	>12 - 24		3										
		6 - 12	INH	2										
		6 - 12	INH	2										
		>24		2										
		>24		3										
		>24		3										
Number of patient with negative culture while being treated with LAI + SOC					10	4	10	11	19	19	21			
Number of patient with negative culture while being treated with PBO + SOC							3	3	NA	NA	NA			

Note. All negative cultures confirmed with no growth in liquid medium.

CF, cystic fibrosis; INH, inhalation; IV, intravenous; LAI, liposomal amikacin for inhalation;

MAC, *Mycobacterium avium* complex; NA, not applicable; NTM, nontuberculous

mycobacteria; PBO, placebo; SOC, standard of care; SQS, Semi-Quantitative Scale.

■ = culture negative (LAI)

■ = culture negative (PBO)

■ = culture negative (off treatment)



FIGURE 7





FIGURE 8





FIGURE 9

